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1. List of abbreviations 
 
cDC conventional dendritic cell 
CRC colorectal cancer 
DC dendritic cell 
NK cells natural killer cells 
PMN-MDSC polymorphonuclear myeloid derived suppressor cell 
TAM tumor associated macrophage 
TAN tumor associated neutrophil 
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3. Introductory summary 
 
3.1 Introduction  
This work focuses on the intestinal myeloid compartment in colitis and colon cancer. 
Intestinal myeloid cells are shaped by their environment and in turn have decisive roles in 
intestinal homeostasis and disease. To gain further insights into the intertwined 
dependencies in the intestinal ecosystem the influence of dietary iron on intestinal myeloid 
cells and colitis, as well as the role of the myeloid effector molecule CCL17 in colitis 
associated cancer and the impact of tumor localization on myeloid cell infiltrates in sporadic 
intestinal tumors were analyzed.  
The intestinal myeloid cell compartment is comprised of granulocytic cells and mononuclear 
phagocytes. The group of granulocytic cells contains neutrophils, eosinophils, basophils 
and mast cells with neutrophils being the most abundant leukocytes and playing crucial 
roles in infection and inflammation. Neutrophils are able to kill intracellular or nearby 
pathogens with their intracellular or secreted granules containing antimicrobial proteins 
which can also modulate other immune cells [1]. Murine neutrophils are characterized by 
the expression of Ly6G and CD11b.  
Neutrophils are crucial for maintaining intestinal homeostasis by their antimicrobial activity 
and have a dual role during intestinal inflammation [2]. While their abundance correlates 
with disease severity and they are responsible for detrimental tissue damage they also 
produce mediators to resolve inflammation and to support epithelial integrity [3, 4]. In the 
tumor, the Ly6G+ CD11b+ population contains classical neutrophils (tumor associated 
neutrophils, TANs) with proinflammatory functions and an immunosuppressive subset 
(polymorphonuclear myeloid derived suppressor cells, PMN-MDSC). For TANs anti- and 
pro-tumoral functions have been described and their role in colorectal cancer (CRC) is 
controversial [5, 6]. The PMN-MDSC subset was shown to promote tumor initiation, 
progression and metastasis [6]. Intestinal mononuclear phagocytes can be subdivided into 
in dendritic cells (DCs) and cells of the monocyte macrophage lineage. Intestinal DCs 
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mainly consist of conventional DCs (cDC), whereas plasmacytoid DCs are rare in the 
intestine. Markers for murine intestinal cDC subpopulations are CD11b, Sirpα, CD103 and 
XCR1. The cDC1 subset expresses CD103 and XCR1 and is low for CD11b, while cDC2 
express CD11b+ and Sirpα+. Within this population and second subset can identified in the 
intestine by co-expression of CD11b and CD103. In colitis cDC1 have a rather anti-
inflammatory role by e.g. their production of retinoic acid and subsequent regulatory T cell 
induction, whereas cDC2 are potent producers of pro-inflammatory cytokines and inducers 
Th17 responses [7, 8]. In the tumor microenvironment both cDC subsets have been shown 
to play crucial roles. As cDC1 are especially capable of antigen uptake and cross-
presentation they are vital for mounting an anti-tumor immune response of cytotoxic CD8+ 
T cells [9]. The cDC2 subset is able to activate CD4+ T cells to elicit Th1 driven antitumor 
responses, which can be enhanced by depletion of regulatory T cells [10]. Intestinal cDC2 
are closely related to intestinal macrophages, which belong to the monocyte-macrophage 
lineage and are derived from circulating monocytes [7]. Expression of CD64 and F4/80 
allows the distinction of monocyte/macrophages from cDC2 in the intestine. In the steady 
state the macrophage pool in the gut is constantly replenished by infiltrating classical 
monocytes in a CCR2-dependent manner [11] unlike in other tissues, where the tissue 
resident macrophages are replenished by yolk-sac derived tissue resident stem cells [12]. 
These monocytes differentiate via an intermediary state into mature, anti-inflammatory 
macrophages [11]. This differentiation process can be followed by monitoring Ly6C and 
MHCII expression. Newly infiltrating Ly6Chi MHCIIlo monocytes develop into inflammatory 
Ly6Chi MHCIIhi monocytes before differentiating into Ly6Clo MHCIIhi macrophages. Colitis is 
marked by a massive increase of infiltrating monocytes, which do not undergo the complete 
differentiation process but maintain high levels of pro-inflammatory activity and 
responsiveness to toll-like receptor ligands [13]. In intestinal tumors an additional MHCIIlo 
macrophage population is found, which has been shown to possess an immunosuppressive 
signature, which is also observed in tumor-associated macrophages (TAMs) in other tumor 
entities [14, 15]. Tumor infiltrating monocytes can secrete tumoricidal mediators, but on the 
3
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other hand differentiate into immunosuppressive TAMs, which promote tumor growth [16]. 
Tumor associated macrophages have been shown to secrete CCL17, a chemokine of the 
C-C family, which is known to bind to the chemokine receptor CCR4, which is expressed 
on T-, natural killer cells (NK-cells), DCs and macrophages [17-21], CCR4. CCL17 has been 
shown to play a role in several inflammatory diseases, such as dermatitis, atherosclerosis, 
as well as in colitis [22-24]. 
 
3.2 Summary of publication 1 - Comparison of iron-reduced and iron- 
supplemented semisynthetic diets in T cell transfer colitis 
Maintenance of intestinal homeostasis is a fine balancing act which can be disturbed by 
multiple internal but also external factors. As intestinal cells are in close contact with the 
environment via the gut lumen, dietary components can act on the cells in the gut directly 
and or via influencing the intestinal microbiota, which colonizes the luminal space. Not only 
macronutrients such as indigestible saccharides, which lead to anti-inflammatory effects via 
short chain fatty acid production by bacteria [25], but also micronutrients like selenium at 
sub-toxic levels have been shown to influence colitis severity [26]. The micronutrient iron 
was shown to induce a pro-inflammatory response in macrophages [27] and luminal iron 
depletion led to disease amelioration in an ileitis model [28]. However, the effect of dietary 
iron reduction in colitis was not investigated so far. In our study, we therefore compared the 
disease severity and the immune cell compartment in the T cell transfer colitis model 
conducted with Rag-deficient recipient mice on iron-depleted, normal, or iron-enriched diets 
[29]. As the transferred T cells were obtained from mice receiving normal chow, we mainly 
studied the effects of dietary iron modulation on the innate immune system and its effects 
on the transferred T cells. While we could observe massive monocyte infiltration and 
increase of the inflammatory monocyte proportion during the course of colitis we did not 
detect differences in immune cell frequencies or effector functions including T- helper cell 
responses with respect to the diets corresponding to the course and severity of colitis which 
was not affected by the iron content of the diets. Thus, we concluded that the frequencies 
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and effector functions of the analyzed intestinal myeloid cells during colitis were 
independent of the luminal iron availability, which is in contrast to the results obtained in the 
ileitis model and illustrates that inflammatory processes in the intestine are highly 
dependent on the location within the gastrointestinal tract. 
 
3.3 Summary of the unpublished manuscript – CCL17 promotes colitis 
associated tumorigenesis dependent on the microbiota 
Colitis is a strong risk-factor for the development of colorectal cancer [30] and chemokines 
are important immune regulators in inflammation and cancer with functions beyond cell 
recruitment [31, 32]. We show in this study that chemokine CCL17 is mainly expressed by 
myeloid cells (cDC2 and macrophages) in the colon and that it is strongly upregulated upon 
inflammation and tumorigenesis. Further we firstly describe a pro-tumorigenic role for this 
chemokine in the development of colitis associated cancer. We found that CCL17-
deficiency influenced the microbiota directly or indirectly and reduced tumor incidence 
without altering the infiltrating immune cell frequencies, highlighting its importance beyond 
its role in immune cell recruitment. Instead, we found effects on tumor infiltrating myeloid 
cell function and on apoptosis in the mucosa of the colon at an early stage of the disease. 
Moreover, our study provides new insights about the gene expression profile of the myeloid 
subpopulations, which infiltrate colitis induced tumors with implications for their 
functionalities in colitis associated cancer development.  
5
Thesis Rebecca Metzger – Introductory summary 
 
 
Figure 1 Graphical abstract of the unpublished manuscript - CCL17 promotes colitis associated 
tumorigenesis dependent on the microbiota. CCL17 is expressed by intestinal macrophages and DCs, 
altering their phenotype. Moreover, CCL17 decreases luminal IgA levels and bacterial IgA coating and leads to 
lowered apoptosis, thereby promoting outgrowth of transformed intestinal epithelial cells. (-) inhibits, (+) 
promotes 
 
3.4 Summary of publication 2 – Increased Incidence of Colon Tumors in 
AOM-Treated Apc1638N/+ Mice Reveals Higher Frequency of Tumor 
Associated Neutrophils in Colon Than Small Intestine 
As illustrated with the above described study, myeloid cells play vital roles for inflammation-
related colon tumor development. However, they also shape the tumor microenvironment 
of sporadic colon tumors and influence their incidence and progression [33]. Unfortunately, 
to date mouse models for sporadic intestinal tumorigenesis show lesions predominantly in 
the small intestine while human intestinal tumors are mostly found in the colon. In this study 
we present a model with 90 % incidence of colon tumors which allows the analysis of small 
intestinal as well as colonic sporadic tumors in parallel and illustrate the marked differences 
regarding the tumor immune cell infiltrate when comparing tumors from small intestinal 
versus colonic locations [34]. We found a 6-fold higher percentage of infiltrating 
granulocytes in colonic versus small intestinal tumors, highlighting the dependency of the 
myeloid immune cell infiltrate on the tumor location. Given the functional relevance of both 
TANs and PMN-MDSC, it is of great importance to model the human situation as close as 
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use this information to design novel treatment strategies for human patients with colorectal 
cancer. The model presented in this study not only provides a closer resemblance to the 
human disease but also allows direct comparisons between the different tumor locations, 
which enables to estimate whether promising findings from the small intestinal tumor 
models might be valid also for sporadic colonic tumors. Furthermore, we found an 
accumulation of CCL17-expressing macrophages and DCs in the colon tumors in this model 
which is in line with our findings in the colitis-associated cancer model and shows that 




Taken together, this work highlights the complexity of the intestinal myeloid cell 
compartment and the multiple dependencies for cell frequencies and functions. It illustrates 
the limitations of dietary interventions in the treatment of colitis, but on the other hand shows 
that CCL17 could be an interesting target for treating colitis associated cancer and points 
to the microbiota as an important player in colitis associated colon tumorigenesis. Further, 
it provides a detailed analysis of the gene expression profiles of myeloid populations in 
colitis induced tumors. This resource can be used to study the contribution of each of these 
populations to the initiation and progression of colon tumors in a well-established mouse 
model which may lead to novel approaches for targeting pro-tumorigenic mechanisms or 
for enhancing myeloid cell mediated anti-tumor responses. My study using the sporadic 
intestinal tumor model shows that small intestinal tumors markedly differ from colonic 
lesions with regard to the infiltration of myeloid cells. These findings have implications for 
developing strategies to prevent the influx or change the functionality of tumor infiltrating 
myeloid cells in intestinal cancers and demonstrate the importance of the location of the 
lesion within the gastrointestinal tract. 
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3.6 Contributions to publication 1 - Comparison of iron-reduced and iron- 
supplemented semisynthetic diets in T cell transfer colitis 
The study was conceptualized by A. Krug, D. Haller and W. Reindl. A. Krug acquired 
funding. 
Data interpretation and conceptualization of the manuscript were performed by all co-
authors. 
Figure 1: A. Markota conducted the experiments with my support in scoring and tissue 
sampling together with L. Jandl and A. Heiseke. E. Dursun provided help with histology. 
Histoscoring was supported by A. Krug.  
Figures 2-5: Flow cytometric analyses were performed by A. Markota with my support in 
tissue sampling and data analysis. 
Supplementary Figure A: I established, performed, analyzed and interpreted the histological 
assessment of the intestinal iron, which showed a reduction of the intestinal iron in the 
dietary iron depleted group and laid the ground for the interpretation of the obtained results 
in the colitis model.  
Supplementary Figure B: Flow cytometric analyses were performed by A. Markota with my 
support in tissue sampling and data analysis. 
Supplementary Table A: K. Eisenächer obtained sample material for hematological 
analysis.  
Supplementary Table B: Flow cytometric analyses were performed by A. Markota with my 
support in tissue sampling, data analysis and - interpretation. 
 
3.7 Contributions to the unpublished manuscript – CCL17 promotes colitis 
associated tumorigenesis dependent on the microbiota 
The study was conceptualized and funding was acquired by A. Krug 
Figure 1: I performed the tissue preparation and the flow cytometric analysis/ immuno-
fluorescent staining/gene expression analysis shown in Figure 1 A-D 
Figure 2: I conducted the experiments and performed the tissue preparation with support of 
S. Krebs. I performed flow cytometric analysis and cell sorting prior to global gene 
expression analysis, as well as the flow cytometric validation of the sequencing results 
(Figure 2 D). Library preparation was performed by R. Öllinger. Data analysis and heatmap 
generation (Figure 2 C, E) was performed with T. Engleitner and K. Lutz, I performed GO 
term analyses shown in Figure 2F. 
Figure 3: The experiments shown in figure 3 were performed with support of S. Krebs, who 
also helped in tissue preparation. I performed immunohistochemical and 
immunofluorescence stainings and analyses as well as the size measurements.  
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Figure 4: I performed the fecal sample preparation for the microbiome analysis, library 
preparation and bioinformatical analyses were done by D. Garzetti. I performed fecal IgA 
staining and flow cytometric analyses with the advice and reagents from V. Friedrich and T. 
Brocker. 
Figure 5: I performed the experiment and flow cytometric as well as gene expression 
analyses. K. Lutz and E. Winheim were participating in tissue preparation. 
Figure 6: I performed the analyses shown in Figure 6A-D. 
Supplementary Figure 1: I performed the flow cytometric analyses shown in supplementary 
Figure 1.  
Supplementary Figure 2: I analyzed the depicted comparisons of surface protein/gene 
expression based on the gene expression data obtained and analyzed with the support of 
R. Öllinger, T. Engleitner and K. Lutz. 
Supplementary Figure 3: I performed the flow cytometric and gene expression analyses 
shown in supplementary Figure 3.  
 
3.8 Contributions to publication 2 – Increased Incidence of Colon Tumors 
in AOM-Treated Apc1638N/+ Mice Reveals Higher Frequency of Tumor 
Associated Neutrophils in Colon Than Small Intestine 
The study was conceptualized and funding was acquired by A. Krug. K.P. Janssen provided 
Apc1638N/+ mice and participated in conceptualization of the manuscript. 
Figure 1: I conducted the experiment and the analyses shown in Figure 1 with the support 
of M. Maruskova in mouse scoring and colony management. 
Figure 2: I conducted the histology shown in Figure 2A. Scoring was done by myself, A. 
Krug and K.P. Janssen. I conducted the gene expression analysis with reagents from K.P. 
Janssen. I established the immunofluorescence staining and analysis. Stainings were 
conducted with the support of S. Krebs. 
Figure 3: I performed the flow cytometric analyses shown in Figure 3A-D with support of M. 
Maruskova in tissue sampling. I performed the gene expression analysis shown in Figure 
3E with the help of S. Krebs in RNA isolation and cDNA preparation.  
Figure 4: I performed the flow cytometric analyses shown in Figure 4A-C with support of M. 
Maruskova in tissue sampling. I established and performed the immunofluorescence 
staining shown in Figure 4D. 
Supplementary Figures 1 and 2: I performed the flow cytometric analyses shown in the 
supplementary figures with support of M. Maruskova in tissue sampling. I established and 
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Abstract
Clinical observations in inflammatory bowel disease patients and experimental studies in
rodents suggest that iron in the intestinal lumen derived from iron-rich food or oral iron sup-
plementation could exacerbate inflammation and that iron depletion from the diet could be  
protective. To test the hypothesis that dietary iron reduction is protective against colitis  
development, the impact of iron reduction in the diet below 10 mg/kg on the course of CD4+  
CD62L+ T cell transfer colitis was investigated in adult C57BL/6 mice. Weight loss as well  
as clinical and histological signs of inflammation were comparable between mice pretreated  
with semisynthetic diets with either < 10mg/kg iron content or supplemented with 180 mg/kg  
iron in the form of ferrous sulfate or hemin. Accumulation and activation of Ly6Chigh mono-
cytes, changes in dendritic cell subset composition and induction of proinflammatory Th1/  
Th17 cells in the inflamed colon were not affected by the iron content of the diets. Thus, die-
tary iron reduction did not protect adult mice against severe intestinal inflammation in T 
cell  transfer induced colitis.
Introduction
Inflammatory bowel diseases (IBD)—ulcerative colitis and Crohn’s disease—are chronic  
inflammatory disorders of the gastrointestinal tract resulting from a dysregulated immune  
response to the intestinal microbiota which is influenced by the genetic susceptibility of the  
host and environmental factors [1]. In addition to dietary intake of macronutrients (fat, carbo-
hydrates and proteins), micronutrients including iron influence the epithelial barrier function,  
the mucosal immune response and directly or indirectly the microbiota [2]. The consumption  
of red meat containing heme iron has been associated with a higher risk for IBD and colorectal  
cancer [3, 4]. Oral iron supplementation is often avoided during phases of active IBD, because  
it is poorly tolerated by some IBD patients and may promote IBD symptoms [5]. Results of  
recent clinical studies however do not provide clear evidence for exacerbation of IBD as a con-
sequence of oral iron supplementation [6]. Animal studies performed in rodents using
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chemically induced erosive colitis models demonstrated a proinflammatory effect of iron in  
the intestinal lumen by showing that high dose oral iron supplementation causes an increase  
in disease activity, inflammatory score and oxidative stress [7–12]. Luminal iron, especially in  
the form of heme iron was shown to induce oxidative stress and cytotoxicity in the intestinal  
epithelium [13]. However, it was shown recently that exposure of intestinal macrophages to  
hemin inhibited their expression of LPS-induced proinflammatory cytokines and this effect  
was reversed by dietary iron reduction [14]. The effect of dietary iron reduction for the devel-
opment of intestinal inflammation has been explored in the spontaneous Crohn’s disease-like  
ileitis model in tumor necrosis factor (TNF)ΔARE mice, which developed less severe intestinal  
inflammation when treated with an iron-reduced diet [15]. In this study, mice fed with an  
iron-free (< 10 mg/kg) semisynthetic diet for 11 weeks depleted hepatic iron stores without  
developing anemia and the protective effect of the iron-reduced diet was still observed when  
systemic iron stores were repleted by parenteral iron administration demonstrating that lumi-
nal iron depletion was responsible for the observed effect [15]. However, iron reduction has  
not been tested as dietary intervention in the T cell transfer induced colitis model, which  
causes T cell driven microbiota-dependent colonic inflammation resembling human IBD.
How luminal iron could promote intestinal inflammation is not fully understood. Excess  
luminal iron induces reactive oxygen species (ROS) and nitric oxide (NO) production which
activate the nuclear factor (NF)-κB signalling pathway and induce inflammatory cytokine pro-
duction [8, 9, 13, 16]. Luminal iron was also shown to trigger endoplasmic reticulum (ER)-
stress leading to apoptosis of intestinal epithelial cells and alterations in the composition of the  
intestinal microbiota [15], but little is known about how changes in the concentration of lumi-
nal iron affect intestinal immune responses. Especially the impact of dietary iron on the mono-
nuclear phagocyte (MNP) system and potential subsequent effects on T cell responses during  
colitis has not beeninvestigated.
The MNP system in the intestine is composed of macrophages and dendritic cells (DCs)  
that have complementary yet distinct functions [17]. Intestinal CX3CR1high macrophages are  
equipped with transepithelial dendrite extensions that enable them to sense and internalize
microbial antigens and micronutrients (including iron) in the gut lumen [18, 19]. Macro-
phages are equipped to take up, store and export iron, but may accumulate iron under inflam-
matory conditions [20]. Iron overload triggers an unrestrained M1 type proinflammatory  
program in macrophages as observed for example in chronic venous leg ulcers and atheroscle-
rosis [21, 22]. Resident anti-inflammatory Ly6Clow intestinal macrophages [23, 24] are contin-
uously replenished by Ly6Chigh blood-derived monocytes [25] that then downregulate Ly6C  
and upregulate MHCII, CD64 and F4/80 [26]. During inflammation, Ly6Chigh monocytes are  
massively recruited to the colon and differentiate into proinflammatory cytokine producing  
macrophages which promote and maintain pathogenic T helper (Th) cells producing IL-17  
(Th17) and Interferon (IFN)-xγ (Th1) in the inflamed colon [27]. Luminal antigens taken up  
by non-migratory macrophages can be transferred to intestinal DCs which migrate to the  
draining lymph nodes (LN) where they present antigens and induce T helper (Th) cell polari-
zation into regulatory (Treg) and effector Th cells [17, 28]. The CD103+ CD11b- intestinal  
DCs which preferentially induce gut-homing Tregs were found to be decreased in the lamina  
propria of the colon during colitis in mice and humans concomitant with an increase in the  
percentage of CD11b+ DCs, which promote differentiation of proinflammatory effector Th  
cells [29, 30, 31, 32].
Here we investigated the impact of dietary iron reduction in T cell transfer induced murine  
colitis as a model of human IBD focusing on the effect of luminal iron on intestinal macro-
phages and DCs as well as Th cell differentiation. Colitis activity was comparable in mice pre-
treated with iron-reduced and iron-supplemented semisynthetic diets in T cell transfer colitis
Dietary iron reduction in T cell transfer colitis
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and no significant differences in the macrophage and DC compartment or in the proinflam-
matory Th1/Th17 cell frequency in the inflamed colon were observed. Thus, our results show  
that dietary iron reduction neither changed the intestinal inflammatory immune response nor  
altered the clinical course of murine experimental colitis induced by T cell transfer.
Methods
Mice
Wild type and Rag1-/- mice (C57BL/6) were bred and held in the mouse facility of the Institute  
of Medical Microbiology, Immunology and Hygiene at the Technical University Munich.
Health monitoring was performed according to the recommendations of the Federation of  
European Laboratory Animal Science Association (FELASA). Sentinels occasionally tested  
positive for Helicobacter spp. Mice entered experiments at 10–12 weeks of age. Mice weresac-
rificed by cervical dislocation. All experimental procedures involving mice were performedin  
accordance with the regulations of and were approved by the local government (Regierung  
von Oberbayern, Az205–2012).
Dietary treatment
The following diets were used: iron-deficient experimental diet (Altromin C1038, <10 mg Fe/  
kg, Altromin, Lage, Germany), iron sulphate containing experimental diet (FeSO4, Altromin  
C1000, 180 mg Fe/kg) or iron-deficient experimental diet (Altromin C1038) supplemented  
with hemin (Sigma Aldrich, Seelze, Germany), which was incorporated into the diet (equalling  
180 mg Fe/kg). Mice were held on standard chow (Harlan Global rodent diet 2018, Harlan,  
Germany) until the age of 10–12 weeks, which was then gradually replaced by the experimental  
diets over a period of 2 weeks. Mice were fed experimental diets for 9 weeks and were then sac-
rificed for analysis or subjected to T cell transfer colitis and continued on the experimental  
diets until the end of the experiments. Mice were held in small groups of 3–4 mice per cage  
throughout the entire experimentaltime.
Colitis model
For T cell transfer colitis, 3 x 105 CD4+CD62L+ splenic T cells were injected intraperitoneally  
into Rag1-/- mice. Colitis activity was evaluated by bodyweight measurements and cumulative  
clinical score (0: absent symptoms, 1: mild symptoms, 2: moderate, 3: severe for inactivity,  
hunched posture, ruffled fur, diarrhea, rectal prolapse and rectal bleeding). Mice were sacri-
ficed when they had lost up to 20% bodyweight compared to the starting weight or when clini-
cal criteria for euthanasia werereached.
T cell isolation
For T cell transfer, T cells were isolated from splenocytes of C57BL/6 WT mice (fed normal  
chow) using CD4+ CD62L+ Isolation Kit II (Miltenyi Biotech, Bergisch-Gladbach, Germany).  
The purity of CD4+ CD62L+ T cells as well as the percentage of Foxp3+ Tregs within the iso-
lated T cell population was evaluated by FACS analysis before each transfer experiment  
(purity: > 90% CD4+ CD62L+ containing 7–10% Foxp3+ as shown previously[33]).
Isolation of cells from mLNs andcolon
Mesenteric lymph nodes (mLNs) were minced and digested with collagenase D (500 μg/mL)  
and DNase I (100 μg/mL) (Roche, Mannheim, Germany) at 37˚C for 30 min. The digested tis-
sue fragments were passed through a100 μm cell strainer.
Dietary iron reduction in T cell transfer colitis
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Colons were excised and attached mesenteric fat was carefully removed. The whole colons  
were cut longitudinally and flushed 3 times with ice cold Ca2+/Mg2+ free HBSS (Invitrogen,  
Thermo Fisher Scientific, Waltham, MA, USA) and then cut in 3 mm long pieces and incu-
bated in Ca2+/Mg2+-free HBSS with 2 mM DTT (Roth, Karlsruhe, Germany) and 5 mM  
EDTA (Invitrogen, Thermo Fisher Scientific) for 30 min at 37˚C stirring in the incubator (5%  
CO2). The treated colon pieces were collected using a 100 μm filter. The filtrate was further  
passed through glass wool (Roth) to remove epithelial cells and isolate the IELs. For isolation  
of LPLs, the remaining colon pieces were digested in RPMI 1640 medium (Thermo Fisher Sci-
entific) containing DNase I (100 μg/mL), collagenase D (500 μg/mL) and collagenase V
(850 μg/mL, Sigma Aldrich, St. Louis, MO, USA) for 30 min at 37˚C and passed through a  
100 μm cell strainer.
Flow cytometry
Cells were stained with fluorescently labelled antibodies against the following surface markers:  
CD3ε CD4, CD11b, CD11c, CD45.2, I-Ab (all eBioscience, San Diego, CA, USA), CD64 (Bio-
Legend, San Diego, CA, USA), CD62L, CD103, Ly6-C (BD Biosciences, Heidelberg, Germany)  
at 1:200 final dilution in FACS buffer (PBS, 2% FCS) with 50% HB197 hybridoma supernatant  
containing Fc blocking antibody 2.4G2 (ATCC, Manassas, VA, USA). Dead cells were  
excluded by propidium-iodide (PI) staining (Sigma Aldrich). For intracellular cytokine stain-
ing single cells from mLNs and colonic LPLs were resuspended in complete medium (RPMI  
1640, 1% GlutaMAX-I, 1% non-essential amino acids, 1% Penicillin/Streptomycin, 1 nM  
Sodium Pyruvate Solution (all from Invitrogen) and β-mercaptoethanol (Sigma-Aldrich), Cell  
were stimulated at 106 cells/96-well with 20 ng/mL Phorbol 12-myristate 13-acetate (PMA)  
(Sigma-Aldrich), 1 μg/ml Ionomycin (Sigma-Aldrich), Golgi Plug (0.2% v/v) and Golgi Stop  
(0.14% v/v) (BD Biosciences) for 6h at 37˚C. Cells were stained for CD3ε and CD4 and then  
treated with IC fixation buffer and 1X Permeabilization Buffer (eBioscience). Intracellular  
staining was performed using anti IL-17A-APC and anti IFN-γ-PE antibodies (BD Biosci-
ence). Intracellular Foxp3 staining was performed using the Intracellular Foxp3 staining kit  
(eBioscience). Flow cytometry analysis was performed using a Gallios Flow cytometer (Beck-
man Coulter, Brea, CA, USA) and data were analysed using FlowJo software (Tree Star, Stan-
ford, USA).
Histology
Colons were cut longitudinally and “swiss rolls” were prepared and fixed in 4% formaldehyde
(Roti-Histofix, Karl-Roth, Karlsruhe, Germany) over night and embedded in paraffin. Tissue
blocks were cut in 4 μm sections and stained with hematoxylin and eosin (H&E). Histological
scoring was performed observer-blinded by adding the scores (0–3) for leucocytes infiltration
and epithelial damage as described (maximal score 6) [34].
Statistical analysis
Statistical analysis was performed using Graph Pad Prism software (Version 6.0, GraphPad  
Software San Diego, CA, USA). The results are presented as mean ± SD. One way ANOVA  
test followed by Tukey‘s post-hoc test was used for multiple comparisons and histologyscores  
were compared using Kruskal-Wallis non-parametric test. p values <0.05 were considered to  
indicate significant differences.
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Results
Dietary iron reduction does not protect against colitis induced by CD4
+ CD62L+ T cell transfer in Rag1-/-mice
It was shown previously that oral iron supplementation influences chemically-induced colitis  
activity in rodents and that dietary iron reduction below 10 mg/kg protects mice from sponta-
neous Crohn’s disease-like ileitis in tumor necrosis factor (TNF)ΔARE mice when compared to  
normal dietary iron content. Therefore, our hypothesis was that dietary iron reduction below  
10 mg/kg could protect mice from colitis and this was tested in C57BL/6/Rag1-/- mice using  
the CD4+ CD62L+ T cell transfer colitis model (see experiment outline in Fig 1A). Hemin was  
used to mimic heme iron contained in red meat or in hemoglobin from mucosal bleeding for  
example. Mice on iron-depleted diet did not develop anemia as determined by blood hemoglo-
bin concentration   13.9 g/dl [35] (w/o Fe: 14.9 ± 3.9; FeSO4: 16.4 ± 3.6; Hemin: 15.8 ± 3.4 g/  
dl; table A in S1 File). After T cell transfer mice lost weight progressively in all 3 groups and by  
day 17 more than 50% of the mice in each group had lost 15–20% of their starting bodyweight  
(w/o Fe: 85.3 ± 8.0, FeSO4: 91.4 ± 9.9, Hemin; 91.2 ± 7.4, mean ± SD, Fig 1B). The bodyweight  
loss was accompanied by similarly increased clinical disease activity in all experimental groups  
(clinical score: w/o Fe: 2.1 ± 1.9, FeSO4: 3.4 ± 1.1, Hemin: 2.5 ± 1.1, mean ± SD, Fig 1C). Leu-
cocytosis and increased haematocrit (indicating fluid loss) were observed in all dietary groups  
during colitis (table A in S1 File). The histological colitis score was also comparable between  
the 3 groups (w/o Fe: 4.7 ± 0.8, FeSO4: 4.2 ± 0.4, Hemin: 4.3 ± 0.5, Fig 1D). Similar degrees of  
epithelial damage with presence of transmural ulcerations and extensive immune cell infiltra-
tion were observed in the colon sections (Fig 1E). Ferric iron was detected by histochemical  
staining in the lamina propria of the inflamed colon at a higher level in mice which had  
received iron-supplemented diets than in mice which were iron-depleted diet (Fig A in S1 
File). These results show that the induction and development of T cell transfer colitis was not  
affected by reduction of the iron concentration in the diet or by the form of iron (ferrous iron  
sulphate or hemin), which was added to the experimental diet.
Recruitment of Ly6C
high
monocytes to the colon is not impaired by dietary  
iron reduction during T cell transfercolitis
The composition of colonic MNPs changes dramatically during colitis and the increased influx  
of blood-derived monocytes into the colon is a sensitive parameter of inflammation. To inves-
tigate whether the luminal iron content has an impact on monocyte recruitment and matura-
tion, the monocyte/macrophage compartment in the colon was analysed by flow cytometry  
after exposure to the experimental diets during T cell transfer colitis (Fig 2A). The frequencies  
of CD11b+CD64+ macrophages in colon lamina propria leucocyte (LPL) and intraepithelial  
leucocyte (IEL) fractions were comparable between the groups (Fig 2B and 2C). Analysis of  
Ly6C and MHCII expression in this population distinguished three distinct subsets:  
Ly6ChighMHCII- (P1) and Ly6ChighMHCII+ (P2) cells are derived from circulating Ly6Chigh  
monocytes and give rise to Ly6ClowMHCII+ macrophages (P3) [25, 26]. The composition of  
the monocyte/macrophage compartment in the colon was not affected by changes in dietary  
iron content as reflected in similar frequencies of P1, P2 and P3 subsets in the 3 experimental  
groups during colitis (Fig 2D and2E).
The development of colitis after T cell transfer resulted in a marked shift of the Ly6Clow P3  
population to the Ly6Chigh MHCII+/- population (P1/P2) in colon LPL compared toRag1-/-
mice treated with the same type of the diet without T cell transfer in all conditions. The ratio  
of Ly6Chigh (P1/P2) to Ly6Clow (P3) populations increased during colitis to a similar extent in
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Intestinal DC subset composition is not affected by dietary iron reduction  
during T cell transfer colitis
Besides the macrophages, DCs play an important role in colitis development as inducers of  
proinflammatory T cell responses [31]. To address if dietary iron content can influence their  
frequency and phenotype in the colon and their shift from the CD103+ to the CD11b+ subpop-
ulations during colitis, DC subpopulations in colon LPL and IEL fractions were analyzed by  
flow cytometry in Rag1-/- mice in the steady state and during T cell transfer colitis after expo-
sure to different diets. Three distinct DC subsets were distinguished based on CD103 and  
CD11b expression (Fig 4A). We observed a decrease in the percentage of CD103+ CD11b-
DCs and an increase in the percentage of CD103+ CD11b+ DCs after colitis induction (table B  
in S1 File). However, modulation of dietary iron content had no major effects on the total fre-
quency of DCs or the DC subset composition in the colon during T cell transfer colitis (Fig 
4B–4E). Thus, the dietary iron content did not influence DC recruitment to the inflamed  
colon or DC subset composition during colitis.
Dietary iron reduction does not influence in vivo T cell differentiation and  
activation during T cell induced colitis
T cell transfer colitis in lymphopenic mice is driven by CD4+ T cells which get activated,  
expand and differentiate in response to commensal bacterial antigens and innate immune sig-
nals delivered by DCs. Therefore, we explored the effect of luminal iron on CD4+ T cell num-
bers and differentiation in this model. The frequencies of CD4+ T cells found in the spleens,  
mLNs and colon LPL and IEL fractions on day 17 after T cell transfer were comparable  
between the different dietary treatments (Fig B in S1 File). A small population of Foxp3+ Tregs  
was detected in mLNs and colon LPL as well as spleen and colon IELs with similar frequencies  
in the 3 dietary groups (Fig 5A and 5C, Fig B in S1 File). The frequencies of CD4+ T cells pro-
ducing IFN-γ+, IL-17A+ or both cytokines after restimulation in mLNs and colon LPL were  
also comparable between the groups (Fig 5B and 5C). Thus, in the T cell transfer colitis model  
dietary iron reduction had no influence on the accumulation of CD4+ T cells in the colon,  
mLN and spleen and their capacity to produce IFN-γ and IL-17 was not affected. We conclude  
that iron deprivation in the diet does not protect adult C57BL/6 mice against severe intestinal  
inflammation in the T cell transfer colitis model and does not change the frequency of relevant  
immune cell populations in the colon and mLNs.
Fig 1. Dietary iron reduction does not protect against T cell transfer colitis. (A) Experimental design for T cell transfer colitis in Rag1-/- recipient  
mice fed with iron depleted (w/o Fe) or iron supplemented experimental diets (FeSO4 or Hemin). (B) Bodyweight development at indicated time  
points after transfer of CD4+ CD62L+ T cells to Rag1-/- mice fed with experimental diets (one of 3 independent experiments with 4–6 animals in 
each  group is displayed; mean ± SD; one way ANOVA, not significant). (C) Clinical colitis scores at indicated time points of mice from (A) (one of 
3  independent experiments with 4–6 animals in each group is displayed; mean ± SD; one way ANOVA, n.s.). (D) Representative H&E staining of 
colon  tissues sections of mice from (A) at day 17 after T cell transfer. (E) Histological colitis scores of mice from (A) (each symbol represents one
animal and  horizontal lines indicate mean values for each dietary group; Kruskall-Wallis test, n.s.).
https://doi.org/10.1371/journal.pone.0218332.g001
all 3 experimental groups and was not affected by the dietary treatment itself (Fig 3A and 3B).  
These results indicate that neither the constant migration of monocytes into the colon and  
their maturation into Ly6ClowMHCII+ macrophages in the steady state nor the increased  
influx of blood-derived monocytes into the colon during colitis were affected by modulation  
of dietary iron in the T cell transfer colitis model.
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Fig 2. No effect of luminal iron depletion on monocyte/macrophage composition in the inflamed colon. Rag1-/- mice were  
treated with iron depleted (w/o Fe) or iron supplemented experimental diets (FeSO4 or Hemin) and colitis was induced by T cell  
transfer. Colon LPLs and IELs were prepared on day 17 after T cell transfer and analyzed by flow cytometry. (A) Gating strategy  
used for characterization of the monocyte/macrophage compartment in LPL and IEL colon fraction. (B, C) The percentages of  
CD11b+ CD64+ monocytes/macrophages within viable CD45+ leucocytes in LPL (B) and IEL (C) colon fractions are shown. (D, 
E)  The percentages of P1, P2 and P3 subsets in LPL (D) and IEL (E) colon fractions are shown. (B-E) Results of one representative
of 2  independent experiments with 4–6 animals in each dietary group are shown. Crossbars indicate mean values; one way 
ANOVA, n.  s.).
https://doi.org/10.1371/journal.pone.0218332.g002
Discussion
Clinical observations in IBD patients and experimental studies suggested that iron in the intes-
tinal lumen derived from iron-rich food or iron supplementation exacerbates inflammation in  
IBD patients [4, 5, 7–12]. This led to the assumption that oral iron replacement therapy for  
iron-deficiency anemia should be avoided during active IBD and that iron reduction in the  
diet may be protective. Indeed, evidence for a protective effect of luminal iron depletion was  
found in a murine model of ileitis [15]. In this model the beneficial effect of luminal iron  
depletion correlated with reduced ER-stress in the epithelium and changes in the microbiota  
composition. In contrast, we found that colitis activity in the T cell transfer induced mouse  
model of colitis was not affected by alterations in the iron content of the experimental diet in  
recipient mice. Examination of the frequency and activation of relevant innate and adaptive  
immune cell populations in the colon during colitis revealed that the iron-reduced diet had no  
significant effect on these parametersof intestinal inflammation.
To investigate the influence of the iron depleted diet on colitis development, we chose to  
study the CD4+ CD62L+ T cell transfer induced colitis model. In contrast to chemically  
induced colitis models in which epithelial disruption is the primary event, T cell transfer colitis  
is driven by microbiota-dependent proinflammatory Th1/17 cell responses. This is a valid pre-
clinical model, that has been widely used for the development of approved drugs, which are  
effective in the therapy of Crohn’s disease and ulcerative colitis, such as anti-TNF-α and anti-
α4β7-integrin antibodies and probiotics [36, 37, 38] for example. The advantage of this model  
is that epithelial disruption is not the primary event as in chemically induced colitis models.
As iron cannot be removed from normal chow, the animals were adapted to an experimen-
tal semisynthetic diet, which was either iron-free (< 10 mg/kg) or contained 180 mg/kg iron  
in the form of FeSo4 or hemin–a concentration of iron corresponding to that contained in  
normal chow [15]. The same semisynthetic diets (with or without FeSo4) have been used in  
the TNFΔARE/WT ileitis model where the iron-reduced diet changed the microbiota composi-
tion and prevented development of inflammation [15]. In that study it was also shown that the  
iron-free diet led to depletion of hepatic iron stores but did not cause anemia. This is in line  
with our results where mice treated with the iron-free diet did not develop overt anemia but  
showed reduced iron staining in colon tissue sections [15].
Purified diets with different iron concentrations have been tested in chemically induced  
colitis models in mice and rats where inflammation is initiated by epithelial disruption and
massive entry of luminal bacteria into the mucosa of the colon. Seril et al. showed using the  
DSS colitis model in 8 weeks old mice, that colitis activity and tumor incidence increased with  
increasing doses of iron (49–490 mg/kg) in the purified diet [12, 39]. Barollo et al. reported  
increased inflammation and tissue damage in the dinitrobenzene sulfonic acid (DNBS)-
induced colitis model in rats fed with a high iron diet (200 mg/kg and 1.7 g/kg) [7]. Further-
more, in several publications, normal chow was supplemented with high doses of iron in dif-
ferent formulations. Carrier et al. observed exacerbation of DSS-induced colitis in rats by  
addition of 3 and 30 g/kg iron pentacarbonyl iron to the chow correlating with oxidative stress,
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Fig 3. Recruitment of monocytes to the colon during colitis is not influenced by dietary iron reduction. (A) The expression of Ly6C and MHCII 
by  CD11b+ CD64+ colonic monocyte/macrophages in the steady state and on day 17 of T cell transfer colitis in Rag1-/- mice fed with experimental 
diets is  shown in the dot plots. Numbers in the quadrants indicate percentages. Representative results of one of 2 independent experiments are 
shown. (B)  Ratios of Ly6Chigh(P1/P2): Ly6Clow(P3) CD11b+ CD64+ cells in colon LPL and IEL isolated from Rag1-/- mice fed with experimental diets 
without colitis  induction and on day 17 after colitis induction by T cell transfer. An increase in the Ly6Chigh to Ly6Clow ratio indicates recruitment of
monocytes to the  inflamed colon. Representative results of one of 2 independent experiments with 4–6 animals per each dietary group are shown 
(mean ± SD; one-way  ANOVA with Tukey’s multiple comparison test, n.s.).
https://doi.org/10.1371/journal.pone.0218332.g003
neutrophil infiltration, NFκB activation and inflammatory cytokine production [8, 16]. Simi-
larly, supplementation with 1% (10 g/kg) carbonyl iron in the chow for 6 weeks started at 4  
weeks of age exacerbated colitis and promoted tumor development in the Azoxymethan/DSS  
mouse model of colitis-associated colon cancer [9]. On the other hand, a recent study using a
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Fig 4. DC subset composition in the colon is not influenced by dietary iron reduction during T cell transfer  
colitis. Rag1-/- mice were treated with iron depleted (w/o Fe) or iron supplemented experimental diets (FeSO4 or  
Hemin) and colitis was induced by T cell transfer. Colon LPLs and IELs were prepared on day 17 after T cell transfer  
and analyzed by flow cytometry. (A) Gating strategy for DC subpopulations in colon LPL and IEL fractions. (B, C)
The  frequencies of DCs within viable CD45+ leucocytes in colon LPL (b) and IEL (C) are shown. (D, E) The 
frequencies of  R1, R2 and R3 subsets within CD64+ CD11c+ MHCIIhigh DCs within colon LPL (D) and IEL (E) are 
shown (one of 2  independent experiments with 4–6 animals in one of each dietary group; each dot represents one 
animal and  horizontal lines indicate mean values; one way ANOVA, n.s.).
https://doi.org/10.1371/journal.pone.0218332.g004
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Fig 5. Frequency of Tregs and proinflammatory Th1/Th17 effector cells is not affected by dietary iron content during T cell mediated  
colitis. Rag1-/- mice were treated with iron depleted (w/o Fe) or iron supplemented experimental diets (FeSO4 or Hemin) and colitis was  
induced by T cell transfer. MLN cells and colon LPLs were prepared on day 17 after T cell transfer and analyzed by flow cytometry. (A)  
Representative dot plots show Foxp3 expression in CD3+ CD4+ T cells isolated from mLNs and colon LPL fraction for the 3 experimental  
groups. Numbers indicate percentages of Foxp3+ cells. (B) MLN cells and colon LPLs were stimulated with PMA/Ionomycin in the presence  
of secretion blockers for 6 hours. Representative dot plots show the intracellular IFN-γ and IL-17A content in CD3+ CD4+ T cells for the  
respective dietary groups. (C) The percentages of Foxp3+ Tregs, IFN-γ single positive, IL-17A single positive and IFN-γ/IL-17A double  
positive Th cells isolated from the indicated organs are shown as mean values ± SD (n = 3 mice per group, one way ANOVA, n.s.).
https://doi.org/10.1371/journal.pone.0218332.g005
chronic low dose DSS colitis model in mice demonstrated that a diet with 500 mg/kg ferrous  
sulfate reduced colitis susceptibility compared to a diet with 50 mg/kg ferrous sulfate [10].
Taken together, most studies that described increased disease severity and tissue damage in  
chemically induced colitis models supplemented oral iron using much higher doses than those  
recommended for oral iron replacement therapy in human patients and much higher than the  
concentrations found in iron-rich foods (e.g. pork liver 180 mg/kg, Canadian Nutrient File,  
Health Canada, 2015). Our study is the first to investigate the impact of iron reduction in the  
diet below 10 mg/kg compared to an iron-rich diet with 180 mg/kg ferrous sulfate or hemin in  
the T cell transfer colitis model and we could not observe a beneficial effect of this interven-
tion. These results contrast with previous observations in the ileitis model in TNFΔARE mice,  
where the same semisynthetic iron-depleted diet reduced inflammation compared to the  
180mg/kg ferrous sulfate supplemented diet [15].
How can we explain the different results of these two studies? One important aspect is the  
different pathophysiology of the models which were used. In TNFΔARE mice intestinal pathol-
ogy is restricted to the terminal ileum and proximal colon like in human Crohn’s disease. Ileal  
epithelial cells have a higher basal level of ER-stress and are more responsive to induction of  
ER-stress ex vivo than colon epithelial cells [40]. Therefore the observed effects of dietary iron  
reduction on ER-stress and intestinal epithelial cell apoptosis may be more pronounced in the  
ileitis model [15] than in the colitis models.
In TNFΔARE mice inflammation is driven by dysregulated TNF-α production in response to  
the microbiota [41, 42] and critically depends on CD8+ T cell responses [43]. In contrast, unre-
strained microbiota-triggered CD4+ Th1/Th17 cells cause inflammation in the T cell transfer  
colitis model. It cannot be excluded that in the T cell transfer colitis model T cells isolated  
from mice fed with iron-free diet would have behaved differently after transfer than T cells iso-
lated from mice fed with iron-supplemented diet. Indeed, it was reported that iron can pro-
mote expression of GM-CSF and IL-2 in T cells by stabilizing RNA binding protein PCBP1,  
which promotes stability of Csf2 and Il2 mRNA [44]. However, CD4+ T cells isolated from  
spleen of TNFΔARE/WT mice fed with iron-free or iron sulfate supplemented diets did not differ  
in their ability to produce TNF-α and IFN-γ after TCR stimulation [15].
Another major difference is the kinetic of the inflammatory response. Ileitis develops spon-
taneously over a period of 8–16 weeks in the heterozygous TNFΔARE mice, whereas severe coli-
tis develops within 2–3 weeks in the CD4+ CD62L+ T cell transfer colitis underour
experimental conditions. The duration of dietary treatment was comparable between the two  
studies (8–11 weeks) and allows for full adaptation to the diet as shown previously [15]. Con-
stante et al. reported that even 4 weeks of experimental diet with different concentrations of  
iron were sufficient to induce changes in the intestinal microbiota composition in adult mic  
[10]. In that study however microbiota changes did not translate into different susceptibility to  
colitis induced by low dose DSS. This is in line with the results of a recent clinical trial, which  
showed that oral iron replacement therapy induces major changes in intestinal bacterial diver-
sity and composition in IBD patients without affecting clinical disease activity [6]. Similarly,  
an epidemiological study published recently found no significant associations of dietary total
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iron and heme iron intake with risk of IBD in two large prospective cohorts (from the Nurses  
Health Study). Only in a subgroup of patients with a specific ulcerative colitis susceptibility  
locus (a functional coding variant of FcγRIIA) heme iron consumption was significantly asso-
ciated with risk of ulcerative colitis suggesting that dietary heme iron may promote the devel-
opment of ulcerative colitis in genetically predisposed individuals but does not have a major  
effect in the general population[45].
It has been reported that calcium phosphate in the diet can counteract cytotoxic and hyper-
proliferative effects of luminal hemin [46] and a hemin-supplemented low calcium diet was
shown to aggravate chemically induced colitis in rats and mice [47, 48]. However, another  
study investigated the effect of hemin-supplemented diet with normal calcium content on  
microbiota and DSS-induced colitis and showed an aggravation of acute DSS colitis by hemin  
in the diet although the diet was not calcium-depleted [49], which may be due to direct effects  
of luminal heme iron on the microbiota. In our study dietary iron reduction led to reduced  
accumulation of iron in the colonic lamina propria and this was prevented by iron supplemen-
tation in the form of iron sulfate or hemin. We observed a similar extent of iron staining in  
colonic lamina propria of mice fed with a hemin-supplemented vs. iron-sulfate-supplemented  
diet with normal calcium content. It is therefore unlikely, but cannot be excluded, that hemin-
supplementation did not affect colitis activity in our study is due to the presence of calcium  
(9450 mg/kg) in thediet.
In our study, we investigated sensitive immunological parameters of inflammation, such as  
recruitment of monocytes into the colon, changes in DC subset distribution, and activation of
Th cells in the colon. Although monocytes/macrophages are equipped to sense luminal iron  
directly, their response during colitis was not different between mice exposed to iron -reduced  
diet or diet supplemented with ferrous sulfate or hemin at moderate concentrations corre-
sponding to those found in iron-rich food. Furthermore, accumulation of transferred CD4+ T  
cells in the colon of Rag1-/- mice and the production of IFN-γ and IL-17 by these cells as well  
as the frequency of Foxp3+ Tregs were unaltered by the iron content of the diet given to recipi-
ent mice. These results indicate that in this model which is driven by a microbiota-dependent  
proinflammatory CD4+ T cell response the reduction of dietary iron in the recipient mice did  
not affect the proinflammatory responses of the transferred T cells. Thus, our results do not  
provide evidence for a protective effect of dietary iron reduction in this standard mouse model  
of colitis. It remains to be investigated if such an intervention could be beneficial in a subgroup  
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Figure A Detection of iron in colon tissue sections
Left panel: Iron was detected in colon tissue FFPE sections obtained from  
mice after T cell transfer colitis by DAB-enhanced Prussian blue staining. The  
number of stained spots per slide was counted. Mean values and SD are  
shown (pooled results of 2 experiments, n = 8 for FeSo4, n=6 for iron-free and  
hemin). * p< 0.025 (unpaired t-test for FeSO4 vs iron-free and hemin vs iron-
free with Bonferroni adjusted significance level). Right panel: Exemplary result  
of iron staining in colon tissue section, counterstained with hematoxylin. Scale  
bar: 50 µm.
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Figure B Frequency of Tregs and proinflammatory Th1/Th17 effector  
cells during T cell mediated colitis
Rag1-/- mice were treated with iron depleted (w/o Fe) or iron supplemented
experimental diets (FeSO4 or Hemin) for 9 weeks and colitis was induced by T  
cell transfer. Cells were isolated from spleen, MLNs, colon LPLs and colon  
IELs on day 17 after T cell transfer and analyzed by flow cytometry. The  
percentages of CD4+ T cells (A) and the percentages of Foxp3+ Tregs within  
CD4+ T cells (B) were determined (mean values ± SD, n= 3 mice per group,  




















2.6 ± 1.4 7.6 ± 3.0 14.9 ± 3.9 43.6 ± 9.1 53.3 ± 1.1 14.4 ± 2.5
During  
colitis




2.3 ± 1.8 7.2 ± 4.1 16.4 ± 3.6 40.9 ± 7.6 50.7 ± 2.0 14.8 ± 1.3
During  
colitis




4.3 ± 3.2 6.7 ± 2.9 15.8 ± 3.4 44.6 ± 8.1 52.5 ± 1.6 13.9 ± 2.2
During  
colitis
9.6 ± 3.8 9.9 ± 1.1 21.5 ± 2.9 61.1 ± 6.3 44.6 ± 2.4 15.4 ± 1.2
*Hematological parameters before and after colitis induction
Rag1-/- mice were treated with three different experimental diets (iron depleted
(w/o Fe) or iron supplemented (FeSO4 or Hemin) diet) for 9 weeks, colitis was
induced by T cell transfer. Blood samples were analysed after 9 weeks of diet
before T cell transfer and on day 17 after T cell transfer. White blood cell count
(WBC); red blood cell count (RBC), hemoglobin (Hb), hematocrit (HCT), mean
corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) were
analysed. Mean and SD are shown (n=7 for FeSO4; n=6 for w/o Fe; n=6 for
Hemin). One-way analysis of variance (ANOVA) was performed to compare
differences between dietary groups. * indicates p < 0.05. Only MCV was











Steady state 38.8 ± 5.1 11.2 ± 3.8 16.6 ± 5.0
Colitis 32.0 ± 3.2 20.3 ± 4.3* 31.0 ± 4.1*
FeSO4
Steady state 42.2 ± 9.0 4.8 ± 3.1 19.2 ± 7.8
Colitis 25.1 ± 5.6* 20.1 ± 4.1* 36.9 ± 9.3*
Hemin
Steady state 33.3 ± 9.0 8.5 ± 2.4 33.3 ± 6.2#
Colitis 22.3 ± 6.3 22.5 ± 11.0* 34.6 ± 6.6
*Frequency of DC subpopulations in colon LPL in steady state vs. colitis  
Cells were isolated from colon LPL and DC subpopulation frequency analyzed  
by flow cytometry after dietary treatment (steady state) or on day 17 after T  
cell transfer into Rag1-/- mice treated with the indicated diets (colitis). The  
percentages of indicated DC subpopulation within the DC gate are shown  
(mean ± SD). * indicate significant differences between colitis and steady  
state (unpaired t test, p < 0.05, n = 4-6 mice per group). # indicates that mice  
receiving hemin-supplemented diet had a significantly higher percentage of  
CD103- CD11b+ cDCs in the steady state compared to the two other diet  
groups (2-way ANOVA, Tukey’s multiple comparison test, p < 0.05).
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Hematological analysis
Blood samples were collected from either facial vein or postmortem by cardiac  
puncture, depending on the time point of the sampling in the feeding  
experiments. For facial blood collection, mice were pinched behind the  
jawbone using a 5 mm lancet and blood was collected into EDTA containing  
collection tubes. Cardiac puncture was performed for terminal blood  collection. 
Mice were sacrificed by CO2 asphyxia. The blood was drawn from  the heart 
using a 0.5 ml insulin syringe and transferred into EDTA containing  collecting 
tubes. Blood samples were diluted in phosphate-buffered saline  (1:3). White 
blood cell count (WBC), haemoglobin (Hb), haematocrit (HCT),  mean 
corpuscular volume (MCV) and mean corpuscular haemoglobin (MCH)  were 
measured by the Clinical Chemistry department using Sysmex XT- 2000i-1 
Hematology Analyzer (Sysmex Europe GmbH, Norderstadt,  Germany).
Iron staining in tissue sections
Ferric iron staining in colon tissue FFPE sections was performed according to  
Meguro et al. (1) using the Iron Stain Kit (Sigma Aldrich) for Prussian Blue  
staining and the DAB-Substrate Kit (Vector Laboratories, Burlingame, CA,  
USA) for enhancement. Counterstaining was performed with Hematoxylin  
(Merck Millipore, Burlington, MA, USA).
Reference
1. Meguro R, Asano Y, Odagiri S, Li C, Iwatsuki H, Shoumura K.  
Nonheme-iron histochemistry for light and electron microscopy: a historical,  
theoretical and technical review. Archives of histology and cytology.  
2007;70(1):1-19.
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Unpublished manuscript – CCL17 promotes colitis associated 
tumorigenesis dependent on the microbiota  
 
Abstract 
Colorectal cancer is one of the most common cancers and a major cause of mortality. Pro-
inflammatory and anti-tumor immune responses play a critical role in colitis associated colon 
cancer. CCL17, a chemokine of the C-C family which is a ligand for CCR4, is expressed by 
intestinal dendritic cells in the steady state and is upregulated during colitis in mouse models 
and in inflammatory bowel disease patients. Using CCL17eGFP-knock in mice we could show 
that during colitis CCL17 was also expressed by macrophages and intermediary monocytes in 
addition to dendritic cells. We characterized the tumor infiltrating monocyte and macrophage 
populations of colitis induced tumors by global gene expression analysis revealing that the 
Ly6Clo MHCIIhi myeloid cells which showed the highest level of CCL17 expression also showed 
a higher expression of genes enriched in cytokine activity, endocytosis and positive regulation 
of the inflammatory response compared to the Ly6Chi monocytes subset and the Ly6Clo MHCIIlo 
macrophages. We found indeed a significantly lower tumor number in CCL17-deficient mice 
compared to control mice after AOM DSS treatment, indicating a functional relevance of 
CCL17 in colitis-associated tumorigenesis. As this effect was microbiota-dependent we 
analyzed the microbiota of CCL17-deficient mice housed separately or together with CCL17-
competent mice and found marked changes in microbiota diversity and composition. Elevated 
cecal IgA concentration and a higher portion of IgA-coated fecal bacteria in CCL17-deficient 
mice were observed together with the observed microbiota changes. While we did not find 
significantly reduced inflammation we observed an increased ratio of pro- vs anti-apoptotic 
gene expression in the colon of separately housed CCL17-deficient compared CCL17-
competent control mice during the early phase of tumor initiation. In addition, alterations in the 
gene expression signatures of the tumor infiltrating myeloid cells were observed in CCL17-
deficient mice. Taken together our results indicate a role of CCL17 in colitis associated 
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tumorigenesis by influencing the composition of the intestinal microbiome, the apoptosis levels 
in the early tumor development and myeloid cell functionality. 
Introduction 
Colorectal cancer (CRC) is the third most frequent malignancy worldwide with increasing 
incidence and has led to almost 860.000 deaths in 2018 [1]. The pathophysiology of CRC is 
multifactorial with genetic, environmental and life style factors playing major roles [2]. There is 
clear evidence that inflammation is closely linked to colorectal tumorigenesis [3]. Inflammatory 
bowel disease (IBD) patients have a 5-to 8-fold increased risk to develop CRC [4]. 
Inflammatory mechanisms play a pro-tumorigenic role also for sporadic CRC which develops 
in the absence of intestinal inflammatory disease [5, 6]. An important driver for inflammation is 
the gut microbiome consisting of more than 100 trillion aerobic and anaerobic bacteria [7], of 
which several have been linked to increased tumorigenesis [8], while others have been shown 
to produce protective metabolites [9]. In the inflammatory tumor microenvironment immune 
cells can have both pro- and anti-tumoral effects [10]. Of the T helper cell subsets (Th1, Th2, 
Th17, Treg) Th1 cells are considered to be the main drivers of anti-tumor immunity [11]. But 
also tumor-infiltrating myeloid cells, such as macrophages and neutrophils, can be skewed 
towards a pro- or anti-tumor activity by the tumor microenvironment [12]. Therapy for 
unresectable CRC includes chemo- and radiotherapy, targeted therapy and immunotherapy 
with limited efficacy [13, 14]. Therefore, new therapeutic strategies which promote anti-tumor 
immunity without causing tumor-promoting inflammation are needed for the treatment of 
advanced CRC. Promising targets for therapeutic intervention are factors of the tumor 
microenvironment including cytokines, growth factors, hypoxia by angiogenesis-blockade [15], 
as well as chemokines. Besides their role for migration and homing of immune cells  [16] 
chemokines can influence immune and cancer cell functionality. For example, it was shown 
that blocking CCR5 and CCL2 induced anti-tumor activity in macrophages [17, 18]. Non-
chemotactic functions, which promoted tumor progression were also described for CCL5, 
which increased S100A4 dependent tumor cell dissemination and metastatic burden and for 
CXCL1, which promoted breast cancer metastasis by activating NFκB signaling [19, 20]. The 
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C-C chemokine CCL17 binds to CCR4 and induces chemotaxis of CCR4-expressing NK cells 
and CD4+ T cells including regulatory T cells (Treg) and effector Th2 and Th17 cells [21-23]. 
The chemotactic activity of CCL17 is partially redundant with that of CCL22 which also binds 
to CCR4 [24, 25]. However, CCL17 specifically promotes migration and activation of murine 
DCs [26-28] and was found to play an important proinflammatory role in models of organ-
specific inflammation, such as atopic dermatitis, neuroinflammation, atherosclerosis, arthritis 
and colitis [26-30]. Its role for tumorigenesis especially in the inflamed colon remained to be 
investigated. CCL17 was shown to be expressed by non-granulocytic CD11b+ myeloid cells, 
such as CD11b+ dendritic cells (DC) and macrophages [31-33], which make up a  major 
proportion of the immune cells in the colonic tumor microenvironment [34].  
The myeloid immune compartment in the colon consists of granulocytic cells and mononuclear 
phagocytes (MNPs). Besides sensing pathogens, MNPs interact with ILC and T- and B 
lymphocytes, while granulocytic cells, predominantly neutrophils, directly destroy pathogens 
by degranulation or uptake and subsequent degradation  [35, 36]. DCs are subdivided in 
conventional and plasmacytoid DCs. Conventional DCs (cDCs) are far more abundant in the 
colon [37, 38] while pDCs which are rare in the intestine have a highly specialized role in the 
anti-viral defense [39]. The cDC population consists of two main subsets with functional 
specializations [37]. The cDC1 subset has been shown to possess superior cross-presentation 
capacities [40], while the cDC2 subset was found to be critical for the defense against bacterial 
and fungal infections [41]. The cDC2 subpopulation is characterized by CD11b and SIRPα 
expression, while cDC1 express CD103 and XCR1 [37]. Further, there is a cDC2 subset which 
is marked by co-expression of CD103 and CD11b and plays a critical role in the induction of 
Th17 and ILC3 responses [41, 42]. Besides DCs, MNPs of the monocyte-macrophage lineage 
are abundant in colonic mucosa. Unlike in other tissues, intestinal macrophages are derived 
from circulating monocytes, which constantly enter the lamina propria of the intestine and 
differentiate into macrophages [43]. Infiltrating monocytes lose their Ly6C expression and 
upregulate MHCII expression during the 5-7 day long differentiation process with Ly6C+ MHCII+ 
representing intermediary or intermediary monocytes with high cytokine production capacities 
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[44]. Intestinal macrophages are predominantly characterized by a high MHCII expression and 
need to be distinguished from cDC2 by CD64 or F4/80 expression. Besides exerting similar 
functions as cDC2 such as Th17 and ILC3 induction [45], intestinal macrophages can promote 
tissue repair and are able to sample luminal antigens, which they transfer  to cDCs [45, 46]. 
Intestinal DCs and macrophages can influence tumor incidence and progression by several 
means: DCs take up and present tumor antigens to T cells to induce adaptive anti-tumor 
immunity; DCs and macrophages release cytokines and other factors with direct and indirect 
effects on tumor development and progression and intestinal DCs and macrophages influence 
the composition of the microbiota e.g. by regulating intestinal IgA production [47-49]. Thus, 
myeloid cell derived CCL17 appeared to be a promising molecule in potentially regulating the 
inflammatory tumor microenvironment of colitis associated colon tumors and we analyzed its 
role in AOM DSS induced tumorigenesis, which closely resembles CAC [50].  
In the current study we have found a strong upregulation of CCL17 expression in AOM DSS 
induced colon tumor tissue and identified intratumoral DCs and macrophages as main CCL17 
producing cell types. We provide evidence for a microbiota-dependent tumor-promoting role 
of CCL17 in this model. 
 
Materials and methods 
Animals and In Vivo Procedures  
CCL17-eGFP mice on the C57BL/6J background (at east 10 generations backcrossed) were 
obtained from the laboratory of Irmgard Förster {Alferink , 2003 #245}, bred in-house and 
rederived into C57BL/JRccHsd mice, purchased from Envigo (Huntingdon, UK). All mice were 
housed under specific pathogen-free conditions. Health monitoring was performed according 
to the recommendations of the Federation of European Laboratory Animal Science Association 
(FELASA). All experimental procedures involving mice were performed in accordance with the 
regulations of and were approved by the local government (Regierung von Oberbayern, 
license numbers: ROB-55.2-2532.Vet_02-13-36 and ROB-55.2-2532.Vet_02-17-22). 
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For AOM DSS treatments, mice were injected with 10 mg/kg Azoxymethane (AOM, Sigma-
Aldrich, St. Louis, USA, #A5486) i.p. and after five days were treated with three cycles of 
Dextran sodium sulphate (DSS, MP-Biomedical, Santa Ana, USA, #02 160110 80) (2.5 % w/w) 
for 5 days each with 2 weeks in between the cycles. The mice were sacrificed on day 85 of the 
experiment or at an earlier time point when they met the euthanization critera. On the day of 
the analysis the colon was cut longitudinally, washed with ice-cold PBS and the tumor numbers 
and sizes were recorded. Tumors of similar sizes were excised and used for flow cytometric 
analyses, histology and gene expression analysis respectively. 
For short term AOM DSS experiments mice were injected 10 mg/kg AOM i.p. and after five 
days were treated with DSS (2.5 % w/w) for 5 days. Four days after completion of the DSS 
treatment the mice were sacrificed and analyzed as described. 
 
Cell Preparation and Flow Cytometry  
After excision of the tumors remaining normal intestinal tissue was cut into 5 mm long pieces 
and incubated with 2 mM DTT (Sigma-Aldrich, #D0632), 10 mM HEPES, 10 mM EDTA in 
HBSS (without Ca2+/Mg2+) for 10 minutes at 37 °C and 125 rpm. Subsequently, tumor and 
normal tissue was digested with DNAse (0.5 µg/ml, Sigma-Aldrich, #10104159001), 
Collagenase D (2.5 µg/ml, Sigma-Aldrich, #11088858001), Collagenase V (5 µg/ml, Sigma-
Aldrich, #C9263) and Collagenase IV (157 Wuensch Units/ml, Worthington, Columbus, USA 
#LS004188) in RPMI-1640 for 30 minutes at 37°C with gentle shaking and pushed through a 
100 µm and a 40 µm filter, which were washed with ice-cold HBSS containing Mg2+ and Ca2+ 
(HBSS+). The obtained single cell suspensions were incubated for 10 min on ice with anti-
CD16/anti-CD32 containing cell culture supernatant and surface-stained with the respective 
antibodies [Supplementary Table 1]  for 20 minutes on ice protected from light. For intracellular 
cytokine staining the cells were restimulated with 20 ng/ml PMA and 1 ug/ml ionomycin for 5 
hours in the presence of Golgi Plug (0.2 % v/v) and Golgi Stop (0.14 % v/v) (BD Biosciences, 
Franklin Lakes, USA, #555029, #554724). For intracellular staining the cells were fixed and 
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permeabilized using the Foxp3 fixation/permeabilization kit (Thermo-Fischer, Waltham, USA, 
#00-5521-00) after surface antibody staining. Cells were analyzed on a Cytoflex (Beckman 
Coulter, Brea, USA) or Fortessa (Beckton Dickinson, Franklin Lakes) flow cytometer or sorted 
using an Aria Fusion (Beckton Dickinson). Data analysis was conducted with FlowJo v. 10 
(Beckton Dickinson). 
Histology, Immunohistochemistry, and Microscopy  
Selected tumors of similar sizes were fixed in 4% PFA for 1 hour at 4°C and subsequently 
incubated in 20% sucrose o/n at 4°C. Tumors were then embedded in OCT (Leica, Wetzlar, 
Germany) and stored in -80°C. For H&E staining cryosections (5–8 μm) were incubated in 
Hematoxylin solution (Merck, Darmstadt, Germany), washed in H2O and subsequently stained 
in Eosin solution (J.T. Baker, Philipsburg, USA), washed in H2O, dehydrated and mounted 
with Roti® Histokitt (Carl Roth, Karlsruhe, Germany). For immunofluorescent staining 
cyrosections (5-8 µm) were blocked with phosphate buffered saline (PBS) containing 5% goat 
serum (Vector Labs, #S-1000) and 0.5% Triton-X-100 for 1h at RT and then stained with 
primary antibodies (anti-GFP, Abcam, Cambridge, UK, #6556; anti-Ki67, Cell Signaling 
Technologies, Danvers, USA, #12202; anti-mouse E-Cadherin BD Biosciences, #610181; anti-
mouse CD3, Thermo-Fischer, #14-0031-82; anti-mouse CD11c, BD Biosciences, #550283) at 
4°C o/n, protected from light. Secondary antibodies were used and incubated for 1h at RT 
(anti-mouse IgG-AF555, Thermo-Fischer, #A32727; anti-rabbit IgG AF488, Thermo-Fischer, 
#A11008; anti-hamster IgG DyeLight647, Biolegend, San Diego, USA #405505). For staining 
nuclei DAPI (Sigma-Aldrich, #D9542) was used. Imaging was conducted with a Leica SP8X 
WLL upright confocal microscope or a Olympus BX41 fluorescence microscope. Quantification 
of Ki67+ cells was performed using ImageJ . The number of total cells (DAPI+) and the number 
of Ki67+ cells (AF488+) were determined and the frequency of Ki67+ cells was calculated. 
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Microbiota analysis was performed as described in [51] with feces instead of rectal swabs as 
sample material.  
Data analysis was conducted with QIIME v 1.9 [52]. Open-reference OTU clustering and 
taxonomy assignment of sequences were done with UCLUST [53] against the Silva database 
Release 119 [54] at the 97% similarity level. Alpha diversity and beta diversity metrics were 
finally calculated, after rarefying over 2,000 sequences per sample. Linear discriminant 
analysis (LDA) coupled with effect size measurement (Lefse analysis) was conducted (non-
parametric Wilcoxon sum-rank test followed by LDA analysis)  [55].  Bray Curtis distance 
matrices were calculated with QIMME for principal component analysis and statistical testing 
was done with Adonis (permutational multivariate analysis of variance using the Bray-Curtis 
distance matrices). 
Gene expression analysis 
qPCR 
RNA was isolated from snap-frozen tissue using Trizol (Thermo-Fischer, #15596018) reagent 
and reverse transcribed using the SuperScript III (Thermo-Fischer, #18080-044) according to 
the manufacturer’s instructions. The real-time PCR was performed on a Light Cycler 480 
(Roche, Basel, Switzerland) using predeveloped primer-probe sets [Supplementary Table 2] 
and the data was analyzed with the 2ddct-Method [56].  
 
RNA-seq 
Library preparation and sequencing was conducted as described earlier [57]. Downstream 
analysis was conducted with R v3.4.4 and DESeq2 v1.18.1, resulting in gene transcript count 
tables, which were subsequently used for gene set enrichment (using the GSEA v4.0.3 Mac 
App) and GO term analyses (using the online tools available on genemania.org, string-db.org,  
reactome.org and geneontology.org). 
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Cecal contents were homogenized in 100 µl 0.5% Tween in PBS per 10 mg cecal content and 
centrifuged at 100 g for 15 min at 4 °C in order to pellet large particles. The supernatant was 
transferred into a new tube, protease inhibitor was added and it was centrifuged for 10 min at 
10000 g at 4°C. The supernatant was transferred into clean tubes and used for quantification 
with an anti-mouse IgA ELISA kit (Thermo Fischer, #88-50450-22) according to the 
manufacturer’s instructions. Serum was directly used for quantification of IgA with the same 
kit. 
Feces were homogenized in 100 µl PBS per 10 mg, centrifuged at 50 g for 15 min at 4 °C and 
the pellet was discarded. After two washes in 1% BSA in PBS the fecal bacteria were stained 
with anti-IgA-PE antibody (Thermo, #12-4204-81) in PBS with 20% normal rat serum and 1% 
BSA and analyzed on a Canto II (Beckton Dickinson) flow cytometer. 
Colon tumor explant culture  
Colon tumors were excised, weighed and cultured in RPMI-1640, supplemented with 10% 
FCS, penicillin/streptomycin, glutamine, non-essential amino acids and 50 mM BME, o/n at 37 
°C, 5% CO2.  
 
Multiplex Cytokine analysis  
Cytokine analysis from cell culture supernatants was performed using the Legendplex mouse 
inflammation panel (Biolegend, #740446) according to the manufacturer’s introductions. 
Statistical Analysis  
For standard statistical analyses Prism v. 7 (Graphpad, San Diego, USA) was used. Unless 
specified otherwise, individual data points, mean and SEM are depicted. Depending on the 
data distribution unpaired, two-tailed Student’s t-tests or Mann-Whitney tests were performed 
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for two-group comparisons. For three- or more group comparisons one-way-ANOVA with Holm 
Sidak’s multiple comparison test or Kruskal-Wallis with Dunn’s multiple comparison tests were 




CCL17 is expressed in cDC and macrophages in the inflamed mucosa of the colon and in 
colon tumors  
In order to gain insights into the role of CCL17 in the formation and progression of colitis 
associated cancer we sought to identify the CCL17 expressing cells in the colon. CCL17 has 
been shown to be expressed in various lymphoid and non-lymphoid tissues predominantly by 
DCs. However, less is known about the contribution of the several DC subsets and the 
expression dynamics upon inflammation and tumorigenesis, especially in the colon. To answer 
the question whether a distinct DC subset expresses CCL17 in the colon and whether the 
expression pattern changes under different conditions  we used the  CCL17-eGFP knock-in 
mice [31] and detected CCL17-eGFP expressing cells by flow cytometry. Within the CD45+ 
CD11b+ Ly6G– lamina propria leucocyte (LPL) fraction of the colon 4 populations were 
distinguished by Ly6C and MHCII expression, Ly6Chi MHCIIlo monocytes (p1), Ly6Chi MHCIIhi 
intermediate monocytes (p2), Ly6Clo MHCIIhi macrophages/DC (p3) and Ly6Clo MHCIIlo cells  
(p4) [Figure 1A]. The Ly6Clo MHCIIhi population was further separated by CD64 expression 
into MHCIIhi macrophages (p5) and CD11b+ cDCs (p6). DCs were separately gated as CD45+ 
CD64- MHCIIhi CD11chi cells and contained CD11b– CD103+ cDC1, CD11b+ CD103– cDC2 and 
CD11b+ CD103+ (DP) cDCs [Figure 1A]. In the steady state 13.2±0.9% cDC2 and 16.4±1.0% 
CD103+ CD11b+ DC were positive for CCL17 expression, whereas the frequency of monocytes 
and macrophages expressing CCL17 was below 1.2 % [Figure 1B]. In the inflamed colon 
during acute colitis induced by dextran sodium sulfate (DSS) also intermediate monocytes (p2, 
9.6±2.0%) and macrophages (p5, 23.1±3.8%) expressed the CCL17-eGFP reporter and the 
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expression in DCs was increased compared to the steady state with the highest expression in 
the CD11b+ CD103+ DC subset (38.2±7.5%) [Figure 1B]. In colon tumors induced by 
administration of Azoxymethan (AOM) and 3 cycles of DSS a significant increase of CCL17 
expressing cells compared to the non-tumorous colon tissue was found within the intermediate 
monocytes, CD11b+ DCs and MHCIIhi macrophages. The expression pattern was similar to the 
inflamed colon with the exception of Ly6Clo MHCIIlo cells, which were not expressing CCL17 
in the inflamed colon (p4, 0.2±0.03%) but contained a small population of CCL17 expressing 
cells in the colon tumor tissue (p4, 2.1±0.5%) [Figure 1B]. CCL17-eGFP reporter expression 
was not detected in other colonic cells than DCs or macrophages in the tested conditions 
[suppl. Figure 1]. The enrichment of CCL17-positive cells in the tumor compared to adjacent 
tissue was also observed by immunofluorescence [Figure 1C]. As GM-CSF is a known inducer 
for CCL17 expression [33], we quantified Csf2 and Ccl17 mRNA expression in the tumor 
tissue. Ccl17 transcripts were found to be 9.1-fold increased in tumor tissue compared to 
adjacent colon tissue in accordance with the higher frequency of CCL17 expressing cells in 
tumors compared to surrounding colon tissue [Figure 1D]. Csf2 transcripts, encoding GM-CSF 
were concomitantly 9.7-fold increased suggesting that CCL17 is induced in the tumor 
microenvironment by locally produced factors including GM-CSF, a known inducer of CCL17 
expression. Thus, our results show that CCL17 expression is increased in colitis-associated 
colon tumors especially in tumor-associated macrophages. 
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Figure 1 Colonic CCL17 expression. Using CCL17-reporter (eGFP) mice we detected CCL17-eGFP 
expressing cells by flow cytometry and determined the phenotype of CCL17 producing cells in the colon 
under different conditions. A Gating strategy for CD11b+ Ly6G- myeloid cells (left) and for dendritic cells 
(right). B CCL17-eGFP reporter expression in steady state (left), DSS-inflamed (mid) and colon tumor 
and adjacent normal tissue (right) in CD11b+ Ly6G- cells (upper row) and DCs (lower row). Mean ± 
SEM. Each data point represents one mouse (n ≥ 3). Histograms show one representative example. 
*p<0.05, unpaired, two-tailed Student’s t-test. Data is representative for n ≥ 3 independent experiments. 
C Immunofluorescence staining of normal colonic (left) and colon tumor (right) tissue stained for GFP 
(green) and E-Cadherin (grey). Scale bar = 10 µm. Data is representative for n > 3 independent 
experiments. D Relative expression of Ccl17 and Csf2 transcripts in AOM DSS induced colon tumor 
tissue (T) and adjacent normal tissue (N).  Mean ± SEM. Each data point represents one mouse (n ≥ 
7). *p<0.05 unpaired, two-tailed Mann-Whitney test. Data is pooled from three independent experiments. 
Differential CCL17- and surface marker expression in tumor infiltrating myeloid cell 
populations 
It is known that the different tumor infiltrating myeloid subpopulations shape the tumor 
microenvironment promoting or inhibiting tumor growth. However, a detailed analysis of these 
cells in the colitis associated cancer mouse model is lacking to date. To further characterize 
these cells in AOM DSS induced tumors whole transcriptome analysis by RNA sequencing of 
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cells, gated as shown in [Figure 2A], was performed. CCL17 expression was mainly  detected 
in Ly6Clo MHCIIhi cells (p3), consistent with the mean fluorescence intensity (MFI) of the 
CCL17-eGFP signal detected by FACS [Figure 2B]. Of the top 200 highly variable genes 
[supplementary PDF] we validated the differential expression of CD209a (DC-SIGN), CD206 
(mannose receptor) and CD24a (Small Cell Lung Carcinoma Cluster 4 Antigen) by flow 
cytometry [Figure 2E], identifying additional markers to distinguish these populations. For flow 
cytometric analyses cDC2 and MHCIIhi macrophages within the Ly6Clo MHCIIhi cells were 
analyzed separately, gated as shown in [Fig 2E], whereas global gene expression analysis 
was performed on the entire Ly6Clo MHCIIhi population due to limited numbers of DCs. The C-
type lectin receptor CD209a (mouse DC-SIGN) was expressed at higher levels on cDC2, 
macrophages and Ly6Chi MHCIIhi cells, than MHClo populations [58]. The CD209a MFI values 
were comparable in CCL17-eGFP+ cells, cDC2, total DCs and MHCIIhi macrophages [Figure 
S2A]. The endocytic mannose receptor CD206 which is known as a marker for 
immunosuppressive tumor-associated macrophages [59] was found to be expressed mainly 
by MHCIIhi macrophages and at low levels by cDC2 and intermediate monocytes. CCL17-
eGFP+ cells showed similar CD206 levels as the cDC2 population [Figure S2A]. When 
comparing the gene expression levels of known markers for pro-inflammatory (M1) and 
suppressive (M2) macrophages [60], several M1 markers (Il1b, Cxcl2, Il1a, Nfkbiz, Peli1) were 
highest expressed in monocytes, followed by MHCIIhi macrophages, while their expression was 
low in intermediary monocytes and MHCIIlo macrophages [Figure S2B]. Regarding the 
analyzed M2 marker genes no such repetitive expression pattern could be found with highest 
expression of Ccl8 in MHCIIhi macrophages, of Chil3 in monocytes and of Cd36 in MHCIIlo 
macrophages. CCL22, the other ligand for CCR4, showed a similar expression pattern as 
CCL17, indicating a coregulation of these chemokines. Taking into account the expression of 
the analyzed M1 and M2 marker genes besides Mrc1 (encoding for CD206) MHCIIhi 
macrophages in AOM DSS induced colonic tumors did not show an overall increase of M2 
marker genes, nor a decrease of M1 marker genes, suggesting that CD206 might not be a 
useful marker for immunosuppressive TAMs in the AOM DSS tumor model. Monocytes were 
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found to express CD24 at the highest levels [Figure 2C, 2D]. While the gene expression levels 
were lowest in Ly6Clo MHCIIhi cells [Figure 2C] the surface protein levels were lowest in Ly6Clo 
MHCIIlo cells [Figure 2D]. Total DCs showed increased CD24 levels compared to cDC2 and 
MHCIIhi macrophages, likely due to higher expression in cDC1 [Figure S2A]. Gene ontology 
(GO) term analysis of the gene clusters with increased expression by the respective 
populations revealed proteolytic activity of monocytes, expression of hemoglobin genes by 
intermediary monocytes, endocytic and proinflammatory activity in Ly6Clo MHCIIhi cells and 
pattern recognition receptor (PRR) binding in MHCIIlo cells [Figure 2E]. These results provide 
insights into the functionality of tumor infiltrating myeloid populations in AOM DSS induced 
tumors. Further, they showed that CCL17 expression is highest in the Ly6Clo MHCIIhi subset 
of tumor-associated myeloid cells, which is comprised by cDC2 and MHCIIhi macrophages and  
is marked by higher expression of CD206 and CD209a and a gene expression profile enriched 
for inflammatory cytokines and endocytosis. 
 
Figure 2 Differential CCL17 and surface marker expression in tumor infiltrating myeloid cell populations. 
Myeloid subsets of tumor infiltrating cells in AOM/DSS induced tumors were analyzed by RNA 
sequencing. A Gating strategy used for sorting of tumor infiltrating myeloid cell populations. B Ccl17 
transcript expression in the sorted myeloid cell populations (left: transcript read counts, right: eGFP-
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mouse (n ≥ 4). C Transcript expression of Cd209a, Mrc1 and Cd24a in AOM DSS induced tumors. Mean 
± SEM. Each data point represents pooled tumors (similar size) of one mouse (n ≥ 4). D Gating strategy 
to separate cDC2 and MHCIIhi macrophages for flow cytometric analyses (left). Mean fluorescence 
intensities and representative histograms of validated surface proteins. Mean ± SEM. Each data point 
represents pooled tumors (similar size) of one mouse (n ≥ 8). E Gene expression of gene clusters used 
for GO term analysis. F Functional gene enrichment analysis for genes with elevated expression in the 
depicted populations. GO term: gene ontology term; FDR: false discovery rate; a-d: used database. a: 
GeneMANIA prediction server, b: STRING database, c: REACTOME pathway database, d: PANTHER 
Classification System 
CCL17-deficient single-housed mice show decreased colon tumor formation in the AOM DSS 
model 
Given the strong upregulation of CCL17 in the colon tumor tissue we investigated whether 
CCL17 plays a nonredundant role in the tumorigenesis of AOM DSS induced colon tumors. 
Therefore CCL17-deficient (homozygous CCL17-eGFP knock-in, ki/ki) and CCL17-competent 
(wt/ki and wt/wt) mice received one injection of AOM and were subjected to 3 cycles of low 
dose DSS as depicted in [Figure 3A]. To control for microbiota mediated effects we bred 
CCL17-deficient mice from a homozygous ki/ki breeding pair for one generation and compared 
the offspring (ki single housed, SiHo) with CCL17-deficient (ki cohoused, CoHo) and with 
CCL17-competent (ctrl) mice generated from a heterozygous breeding pair. Both breeding 
pairs were derived from the same heterozygous breeding pair to minimize genetic drift between 
the experimental groups. There was no difference in the relative bodyweight during AOM DSS 
treatment between the experimental groups. However, tumor formation was significantly 
decreased in single-housed CCL17-deficient mice (ki SiHo, 12.4±1.3 tumors) compared to 
CCL17-competent (ctrl, 16.1±1.1) and cohoused CCL17-deficient mice (ki CoHo, 19.9±2.0). 
The tumors did not show overt histological differences between the experimental groups 
[Figure 3E]. The average tumor area was slightly elevated in the single-housed CCL17-
deficient group compared to the other groups (single-housed CCL17-deficient 6.5±0.5 mm2, 
CCL17-competent 4.7±0.4 mm2, cohoused CCL17-deficient 5.0±0.4 mm2) and a trend towards 
a higher percentage of Ki67+ tumor cells in this group was observed, indicating that tumor 
multiplicity but not tumor growth is reduced in single-housed CCL17-deficient mice [Figure 3F, 
3G].  
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Figure 3 CCL17-deficient single housed mice show decreased tumor formation upon AOM DSS 
treatment. Single-bred/-housed CCL17-deficient (ki/ki) and cohoused CCL17-ki/ki and CCL17-
competent (wt/ki and wt/wt) littermates were treated with AOM and three cycles of DSS. A Experimental 
scheme of the AOM DSS treatment. AOM: Azoxymethane, DSS: Dextran sulfate sodium, dissolved in 
drinking water (%wt/wt). B Breeding strategy for obtaining the experimental groups ctrl (CCL17-wt/wt 
and CCL17-wt/ki), ki CoHo (CCL17-ki/ki with CCL17-wt/wt and CCL17-wt/ki cohoused littermates) and 
ki SiHo (CCL17-ki/ki with CCL17-ki/ki littermates, separately housed from CCL17-wt/wt and CCL17-
wt/ki mice). C Relative bodyweight during AOM DSS treatment. The bodyweight was normalized to the 
starting weight at the beginning of each DSS cycle. Open rectangles: ctrl, filled circles: kiSiHo, filled 
rectangles: kiCoHo. Mean ± SEM. Each data point represents one mouse (n ≥ 11, pooled from two 
experiments). D Number of tumors per mouse after AOM DSS treatment. Each data point represents 
one mouse (n ≥ 11, pooled from two experiments). Mean ± SEM. *p<0.05, two-tailed Mann-Whitney 
test. E Representative hematoxylin-eosin (H&E) stained cryosections from AOM DSS induced tumors. 
Scale bar: 10 µm. F Area per tumor. Each data point represents one tumor (n ≥ 98). Line: median, 
*p<0.05, unpaired, two-tailed Student’s t-test. G Left: Percentage of Ki67+ cells, determined by 
immunofluorescence staining (Ki67+/DAPI+ cells). Each data point represents one mouse (n ≥ 3). Mean 
± SEM. Right: Representative section stained for DAPI (blue), Ki67 (magenta) and E-Cadherin (grey). 
Scale bar: 10 µm.   
CCL17 deficiency leads to an altered microbiota  
The observed reduction in tumor numbers in CCL17-deficient mice appeared to be microbiota 
dependent, as CCL17-deficient mice cohoused with CCL17-competent littermates did not 
show this phenotype. To determine microbial changes in the single-housed CCL17-deficient 
mice we analyzed the steady state fecal microbiota of those mice in comparison with that of 
controls and CCL17-deficient mice cohoused with controls. As the microbiota of CCL17-
deficient and competent littermates were very similar, as expected, we merged these two 
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groups for the statistical analyses. When comparing the microbiota of CCL17-deficient single 
housed and the cohoused mice, differences both in the alpha- and in the beta diversity of the 
respective microbiota were detected [Figure 4A, 4B]. The number of observed operational 
taxonomic units (OTUs) was significantly smaller in feces of single housed CCL17-deficient 
mice than in the feces of the cohoused groups [Figure 4A]. The Bray-Curtis principal coordinate 
analysis revealed a significant alteration of the bacterial composition in the feces of single 
housed CCL17-deficient mice versus cohoused control mice [Figure 4B]. Further analysis 
using the LEfSE (linear discriminant analysis effect size) method showed a reduced 
abundance of the genus Lactobacillus and the Proteobacteria phylum in the feces of cohoused 
mice, while the genus Akkermansia, the Ruminococcaceae family and the Peptococcaceae 
family were enriched in the feces of single-housed CCL17-deficient mice [Figure 4C] coinciding 
with less tumors developing in these mice in the AOM DSS model.  
Next, we wanted to investigate the underlying cause of these marked differences in the 
microbiota of single housed CCL17-deficient mice compared to their cohoused counterparts. 
Secretory IgA produced constitutively in response to commensals is an important component 
of the intestinal barrier, regulates microbiota composition and maintains intestinal homeostasis 
[49, 61]. Bacterial IgA coating has been suggested to influence microbial composition both by 
promoting bacterial clearance [61] and creating protective niches for the IgA-bound bacteria 
[62], depending on the environmental setting and the respective bacteria. We found 
significantly more IgA-coated bacteria in the feces of single-housed CCL17-deficient mice than 
in control mice [Figure 4D]. IgA levels were significantly elevated in the cecal lumen but not in 
the serum of single-housed CCL17-deficient mice [Figure 4E], demonstrating that only 
intestinal and not systemic IgA production is altered in these mice. These results suggest that 
secretory IgA contributes to the establishment of an altered microbiota in CCL17-deficient mice 
which is protective against colitis-induced tumor formation. 
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Figure 4 CCL17 deficiency leads to an altered microbiota. A Number of observed OTUs in the feces 
of steady state ki SiHo vs ctrl& ki CoHo mice. Mean ± SEM (n ≥ 7). *p<0.05 unpaired, two-tailed 
Student’s t-test. B Bray-Curtis principal coordinate analysis of the microbiota composition in ki SiHo and 
ctrl&ki CoHo mice. Each data point represents one mouse. *p<0.05 Adonis (permutational multivariate 
analysis of variance using the Bray-Curtis distance matrices). C Linear discriminant analysis effect size 
(LEfSE) analysis. Green: taxa enriched in ctrl & ki CoHo, red: taxa enriched in ki SiHo. LDA: Linear 
discriminant analysis. D Left: Percentage of IgA-coated bacteria, determined by flow cytometry. Each 
data point represents one mouse (n = 5). Mean ± SEM.  *p<0.05 unpaired, two-tailed Student’s t-test. 
Right: Representative contour plots of ctrl and ki SiHo fecal samples. E Cecal (left) and serum (right) 
IgA concentration in ctrl and ki SiHo mice. Each data point represents one mouse (n = 5). Mean ± SEM.  
*p<0.05 unpaired, two-tailed Student’s t-test.  
Single-housed CCL17-deficient mice show similar weight loss and inflammation after short 
term AOM DSS treatment  
In the AOM DSS model the AOM injection and the first cycle of DSS-induced intestinal 
inflammation and regeneration are decisive for tumor initiation and early tumor promotion, 






















































































-4 -2 0 2 4
LDA SCORE (log 10)
ki SiHo




















CCL17 promotes colitis associated tumorigenesis dependent on the microbiota –  Results 
 (18)  
maintenance and progression. In order to investigate the events during the initiation phase we 
injected single-housed CCL17-deficient mice and control mice (wt/ki) with AOM followed by 
one cycle of DSS and analyzed the mice during the regeneration phase on d4 after stopping 
exposure to DSS [Figure 5A]. We did not observe significant differences in weight loss during 
the inflammation phase (day 8 – 12) or in weight gain during the regeneration phase (day 12 
– 14) as shown in [Figure 5B]. Histological examination did not reveal major differences in 
epithelial damage, leucocyte infiltration and regenerative responses of the epithelium [Figure 
5C]. Also, the expression of the antimicrobial proteins Muc2 and Reg3g was not altered in 
single-housed CCL17-deficient mice four days after ending DSS treatment. However, the 
transcript level ratio of proapoptotic Bax and antiapoptotic Bcl2, an indicator for apoptotic 
activity [63] was significantly increased in the colon tissue of these mice, while the relative 
mRNA expression of the proliferation marker Pcna and the tissue repair promoting cytokine 
Il22 was not altered. These results indicate increased apoptosis, but comparable proliferative 
response in the colon of single-housed CCL17-deficient mice during the regeneration phase.  
We also analyzed the infiltration by inflammatory cells after short term AOM DSS treatment by 
flow cytometry and found no difference in the frequency of CD45+ cells (40.0±3.1 % in CCL17-
competent vs 39.15±4.85 % in CCL17-deficient single-housed mice) in the colon between the 
experimental groups. The frequencies of neutrophilic granulocytes, which make up the majority 
of the myeloid cells, as well as the percentages of monocyte subsets and MHCIIhi 
macrophages within the CD11b+ non-granulocyte fraction were not altered. The composition 
of the colon DC compartment was also not changed. Only a significantly higher percentage of 
MHCIIlo cells was found in the colon of single-housed CCL17-deficient mice [Figure 5F]. The 
mRNA expression of the proinflammatory cytokines Ifng, Il17, Il12, Tnfa, Il1b and Il6 in whole 
colon tissue was not altered, indicating a similar inflammatory activity after the short term AOM 
DSS treatment. It is therefore unlikely that reduced tumor numbers in single housed CCL17-
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Figure 5 Single housed CCL17-deficient mice show similar weight loss and inflammation after 
short term AOM DSS treatment. Single-housed CCL17-deficient and control mice were injected AOM 
followed by one cycle of DSS and were analyzed during the regeneration phase. A Experimental 
scheme of AOM DSS treatment. B Relative bodyweight during AOM DSS treatment. Open rectangles: 
ctrl, filled circles: ki SiHo, Mean ± SEM (n ≥ 4). C Representative H&E stained distal colon sections from 
AOM DSS treated mice. Scale bar: 10 µm. D Colonic Relative expression of Muc2 and Reg3g after 
AOM DSS treatment. Mean ± SEM. Each data point represents one mouse (n = 4). E Left: Ratio of 
Bax/Bcl2 transcript levels. Right: Relative expression of Pcna and Il22. Mean ± SEM. Each data point 
represents one mouse (n = 4). *p<0.05 unpaired, two-tailed Mann-Whitney test. F Colonic myeloid 
immune cell infiltration after AOM DSS treatment. Left: gating strategy and representative plots for 
CD11b+ Ly6G- myeloid cells (upper panel) and dendritic cell subsets (lower panel). Right: Quantification 
of cell frequencies. Mean ± SEM. Each data point represents one mouse (n = 4). *p<0.05 unpaired, two-
tailed Student’s t-test. G Colonic relative expression of cytokines after AOM DSS treatment. Mean ± 
SEM. Each data point represents one mouse (n = 4). 
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Characterization of the tumor immune infiltrate of CCL17-deficient single housed mice reveals 
altered gene expression signatures in the myeloid cell compartment 
Colon tumor development, maintenance and progression is influenced by the tumor 
microenvironment (TME) which is shaped by innate and adaptive immune cells infiltrating the 
tumors and by microbiota-dependent signals [64, 65]. In addition, anti-tumor immune 
responses play a role also in inflammation-driven tumors  [10]. As CCL17 is highly expressed 
in AOM DSS induced tumors by macrophages and DCs, we hypothesized that it might 
influence the immune cell composition in the tumors. Analysis of the immune cell infiltrate of 
AOM DSS induced tumors by flow cytometry revealed no differences in the frequencies of 
CD45+ immune cells, CD11b+ myeloid cells or DCs and no change in the frequencies of 
monocyte, macrophage and DC subpopulations between single-housed CCL17-deficient mice 
and the control groups [Figure 6A, 6B]. However, global transcriptome analysis of myeloid cells 
isolated from AOM DSS induced tumors revealed that monocytes (p1) from tumors of single-
housed CCL17-deficient mice were enriched for genes involved in proteasomal degradation 
(e.g. Psmc2 and Psmb1, which encode for proteasome subunits) and oxidative 
phosphorylation (e.g. Uqcr10 encoding for a complex III subunit and multiple genes encoding 
for the NADH dehydrogenase complex). Ly6Clo MHCIIhi (p3) cells from these tumors showed 
an even stronger enrichment for these gene signatures as well as an enrichment for genes 
involved in lysosomal activity (e.g. Psap and Hexb, which are crucial for lipid degradation) 
indicating increased endocytosis/phagocytosis levels of myeloid cells in colon tumors of single-
housed CCL17-deficient mice [Figure 6C]. Moreover, the supernatant of tumor explant cultures 
of single-housed CCL17-deficient mice contained significantly less IL-1β compared to the 
controls [Figure 6D]. These results indicate functional differences of the myeloid cell 
compartment in tumors of CCL17-deficient single housed group, which coincided with reduced 
tumor numbers. 
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Figure 6 Altered gene expression signatures in tumor associated myeloid cells. Tumor infiltrating 
immune cells in tumors of ctrl, ki SiHo and ki CoHo were analyzed. A Frequency of total immune cells 
(far left), Percentage of tumor infiltrating CD11b+ myeloid cells (left), granulocytes (right) and 
monocytes, intermediate monocytes, MHCIIhi and MHCIIlo macrophages (far right) in tumors of ctrl, ki 
SiHo and ki CoHo mice. Each data point represents one mouse (n ≥ 4). Mean ± SEM. B Percentages 
of total DCs (left) and DC subsets (right) in tumors of ctrl, ki SiHo and ki CoHo mice. Each data point 
represents one mouse (n ≥ 4). Mean ± SEM. C Gene set enrichment analyses of tumor infiltrating 
CD11b+ Ly6G- myeloid cell populations p1-p4  from ki SiHo and ctrl mice. The color intensity of the 
circles denotes the significance level (false discovery rate, FDR); the circle diameter reflects the 
normalized enrichment score (NES). Blue/red indicates the group in which a signature was positively 
enriched; n ≥ 4 biological replicates for each group. D Concentration of IL-1β in the supernatant of tumor 
explant cultures from ctrl and ki SiHo mice.  Each data point represents one mouse (n = 3). Mean ± 
SEM. *p<0.05 unpaired, two-tailed Student’s t-test. 
Innate and adaptive lymphocytes also influence the TME and may have tumor-promoting as 
well as anti-tumor activity. We found no difference between the experimental groups in the 
percentages of B cells, but a trend towards lower T cell frequencies in tumors of single housed 
CCL17-deficient mice [suppl. Figure 3A, B]. The T cell distribution within the tumor tissue was 
not altered between the groups [suppl. Figure 3C]. The percentages of the CD8-, CD4- and 
Treg-subsets, as well of NK and NKT cells were similar between the groups [suppl. Figure 3D]. 
Effector functions of intratumoral lymphocytes, measured by intracellular IFN-ɣ and IL-17, 
surface CD69 protein levels as well as Gzmb, Il17 and Ifng gene expression appeared to be 
unaltered [suppl. Figure 3E-G]. These results show that the alterations in tumor-associated 
myeloid cell functionality observed in single housed CCL17-deficient mice are not connected 
with increased anti-tumor effector T cell responses. 
Taken together, we find that the reduced tumor load in CCL17-deficient mice is dependent on 
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increased ratio of pro- vs anti-apoptotic gene expression in the colon during the early phase of 
tumor development as well as with functional changes in tumor-infiltrating myeloid cells. 
Discussion 
We found CCL17 expressed in the steady state colon by the CD11b+ dendritic cell subsets, 
which was observed in other organs as well [27, 32]. While CCL17 is absent in the steady state 
spleen due to IFN-ɣ signaling in DCs, it can be induced in splenic DCs by systemic application 
of GalCer, which to IL-4 and GM-CSF secretion by NKT cells [32, 66]. This illustrates that 
CCL17 expression is highly dependent on external stimuli and is in line with our observation 
of strong CCL17 induction in DSS induced colon inflammation and AOM/DSS-induced colon 
tumors. Upregulation of CCL17 expression in intestinal DCs was also observed in another 
colitis model [26], in skin lesions of an atopic dermatitis model [28] and in the CNS during EAE 
[27]. CCL17 expression by macrophages was observed in joint inflammation [30] and 
peritonitis  [33], as well as in a subset of TAMs in a melanoma model [67] and in intestinal 
tumors developing in APC-mutant mice, which is in line with our observations in the CAC model 
[34]. CCL17 is one of the hallmark genes expressed by M2-polarized macrophages [60]. The 
present study is the first to provide detailed information about the expression of CCL17 in the 
colonic monocyte, DC and macrophage subpopulations in inflammation related colon 
tumorigenesis. 
In order to characterize the CCL17 expressing population in AOM DSS induced tumors further, 
we analyzed the transcriptome of the major non-granulocytic tumor-infiltrating CD11b+ myeloid 
cell populations and found population-specific gene enrichments with functional implications. 
In the steady state Ly6Chi MHCIIlo monocytes are recruited to the colon where they differentiate 
via Ly6Chi MHCIIhi intermediary cells into Ly6Clo MHCIIhi macrophages acquiring a tissue-
specific gene signature during the differentiation process [68]. We found an enrichment of 
hemoglobin-genes in intermediary monocytes, which is in line with findings by Kraft-Terry et. 
al, who described transcription of hemoglobin genes during early monocyte to macrophage 
differentiation [69]. 
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Among the genes encoding for known cell surface receptors, we found Mrc1, Cd209a, and 
Cd24a among the Top 200 highly variable genes. Higher expression of Cd206 and Cd209a in 
Ly6Clo MHCIIhi cells compared to the other analyzed populations could be confirmed on protein 
level by flow cytometry, while CD24 surface expression was highest in the monocyte 
subpopulations followed by MHCIIhi macrophages and DCs. CD24-deficient mice show 
reduced susceptibility to DSS-induced colitis and to tumor formation in the AOM/DSS induced 
model, but the function of CD24 on monocytes and macrophages was not investigated in this 
study [70]. It was shown that CD24 by interacting with human Siglec 10 or mouse Siglec G 
dampens the inflammatory response to tissue injury [71]. CD24 expressed on cancer cells by 
interacting with Siglec G on macrophages inhibits phagocytosis activity against tumor cells [72] 
and CD24 expressed on tumor-infiltrating myeloid cells could have a similar function. It was 
shown for example that silencing of CD24 increased phagocytosis of B. burgdorferi and TNF-
a induction in RAW macrophages [73]. The C-type lectin CD209a is related to high endocytic 
activity and the initiation of T cell responses [58]. We found significantly higher Cd209a gene 
expression in Ly6CloMHCIIhi cells which could be confirmed on surface protein level and we 
observed an enrichment for other genes involved in receptor-mediated endocytosis in this 
population which at the same time expresses the highest levels of CCL17. Also, the mannose 
receptor CD206 was found to be significantly higher expressed in Ly6CloMHCIIhi cells with 
highest expression in MHCIIhi macrophages, in line with the report by Schridde et al.  who 
analyzed steady state colonic myeloid cells [68]. CD206 is widely used as a marker for 
immunosuppressive macrophages in the tumor environment [74-77]. However, we found 
highest CD206 surface levels on MHCIIhi macrophages, while other genes related to 
immunosuppressive macrophages were not significantly higher expressed in this population 
and the expression of several pro-inflammatory genes was not significantly lower in MHCIIhi 
macrophages, but in MHCIIlo macrophages, compared to the monocyte population which 
showed the highest expression of pro-inflammatory marker genes. This is consistent with other 
studies which identified  MHCIIlo macrophages as the suppressive macrophage population in 
different tumor models [77, 78]. Thus, our results indicate that the population of MHCIIhi 
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macrophages and cDC2 which contains the CCL17 expressing cells is especially equipped 
with receptors for antigen uptake and that CD206 might mark macrophages of different 
functionality in AOM DSS induced colon cancer than in other tumor models, highlighting the 
importance of the tissue microenvironment for macrophage phenotype and functionality. 
Our data shows that CCL17 is expressed by intratumoral myeloid populations, which are 
relevant for tumor development. Lower tumor number in CCL17-deficient mice indicate a  role 
of CCL17 in AOM DSS induced tumor development itself. However, while inflammation is a 
major driver in the AOM DSS induced tumor model [50], we did not find overt differences in 
inflammation between the groups, which is in contrast to our previous results, which we 
obtained in the acute DSS colitis model with higher doses of DSS [26]. Other studies, finding 
reduced [79, 80] or increased [81] tumor numbers despite similar inflammation or even a 
reduced tumor load with increased inflammation [82, 83] illustrate that other factors than 
inflammation severity can be decisive for tumor induction in this model. Moreover, we found 
that the difference in tumor multiplicity was abolished when CCL17-deficient mice were 
obtained from heterozygous breedings and cohoused with CCL17-competent littermates 
highlighting the importance of the microbiota as has been observed for other knockout mice in 
the AOM/DSS model [84, 85]. Despite a reduction of the tumor number in CCL17-deficient 
mice their tumors were not smaller but even slightly larger compared to the other groups. Thus, 
our results show a reduced tumor number in CCL17-deficient mice without reduction in 
inflammation severity and tumor size, which is abolished upon cohousing the mice, indicating 
a role of the microbiota in the protective effect of CCL17 deficiency. 
In congruence with the observed effect of separate housing on tumor numbers we found 
altered alpha- and beta-diversities in single housed CCL17-deficient mice compared to the 
control groups. The studies of Tschurtschenthaler et al. and Man et al. and the observation 
that germ-free mice develop higher tumor numbers after AOM DSS treatment [84-87] clearly 
show that the microbiota composition is a crucial determinant of the tumor number in this 
model. We found decreased levels of Proteobacteria in single-housed CCL17-deficient mice 
which was associated with lower tumor incidence in other studies [88, 89]. The role of 
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Akkermansia, which we found increased in single-housed CCL17-deficient mice is not that 
clear, as both pro- and anti-inflammatory/tumorigenic effects have been reported for increased 
abundance of this phylum [90-92]. Similarly, Wu et al. have found in the AOM DSS tumor 
model a positive correlation of tumor multiplicity with the abundance of the  Lactobacillus 
phylum, which we found decreased in single housed CCL17-deficient mice, whereas Chen et 
al. found a decreased abundance upon AOM DSS induced tumor development [93, 94]. One 
possible underlying mechanism for the altered microbiota composition is a direct, non-
redundant effect of CCL17 on the intestinal microbiota. Alterations of the microbiota by 
chemokine-receptor deficiency have been described before [95]. Chemokines of the C-C 
family possess a structure similar to defensins and high anti-microbial activity has been shown 
for the members CCL28 and CCL20 [96-98]. For CCL17 only a low to moderate antimicrobial 
activity has been shown against E.coli and S.aureus in vitro at high doses [98], but it cannot 
be excluded that CCL17 might influence the bacterial composition in the colon directly. Another 
regulator of the intestinal microbiota is intestinal IgA, produced by plasma cells in the peyers 
patches (T-cell dependent (TD) IgA production) or in isolated lymphoid follicles (ILF) (T-cell 
independent (TI) IgA production) [49]. The functional consequences of IgA binding to intestinal 
bacteria have shown to be diverse and range from protective effects  [61, 62, 99-101] to 
inhibition of bacterial motility [102], enhanced clearance [61] or reduced bacterial fitness [103] 
e.g. by altering bacterial gene expression [104]. Whether intestinal IgA confers supportive or 
negative effects on the microbiota was shown to depend on its affinity to its epitope, which can 
be single- or cross species-specific [61, 105, 106]. Palm et. al found that IgA+-bacteria from 
human colitis patients induced colitis when they were transferred to germ-free mice [107], Kau 
et al. found higher IgA+ levels in healthy donors compared to their malnutritioned twins [108], 
whereas D’Auria et al. found specific IgA-coating of rare bacterial taxa such as 
Sphingomonadaceae [109]. We found a significantly higher percentage of IgA-coated fecal 
bacteria in single-housed CCL17-deficient mice and higher cecal IgA levels with unchanged 
serum levels. Moreover, we observed a lower number of different fecal OTUs in single-housed 
CCL17-deficient. Thus, higher IgA-coating may reduce tumorigenic OTUs in the single-housed 
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CCL17-deficient mice. It has been shown that myeloid cells are able to change the microbiota 
[92, 110, 111] and that CD11b+ CD103+ dendritic cells, which produce high levels of CCL17 in 
tumor and normal intestinal tissue are important for TI IgA responses as they are able to 
support of B cell differentiation [112]. Thus, CCL17 deficiency could lead to an altered 
microbiota either directly or indirectly by regulating intestinal IgA responses.  
As we observed reduced tumor numbers in single-housed CCL17-deficient mice we analyzed 
the mice after short term AOM DSS treatment to detect changes in early tumor development. 
No evidence for reduced inflammation or altered proliferative response was found at this early 
time point. This in contrast to other studies, such as Mc Donough et al., who find increased 
colitis severity and elevated tumor numbers in Mtg16 deficient mice or Huber et al., who find 
IL-22 dependent increased proliferation after epithelial damage in IL-22 BP deficient mice and 
a subsequent increase in tumor number at the end of the AOM DSS treatment [113, 114]. The 
increased Bax/Bcl2 gene expression ratio in distal colon tissue of single-housed CCL17-
deficient mice indicated elevated apoptosis levels after one cycle of DSS treatment. It was 
shown previously that apoptosis during tumor initiation reduces tumor numbers independent 
of colitis severity in the AOM DSS model when carcinogen-exposed enterocytes undergo 
apoptosis instead of forming a tumor  [115]. Interestingly, a higher tumor incidence together 
with decreased tumor sizes and reduced apoptosis levels in the beginning of the treatment 
have also been observed in mice deficient for Parp–1. In this study Parp–1 was found to 
increase mutation induced cell death in the early stages and thereby reduced tumor incidence 
but promoted tumor progression [116]. CCL17 might influence IEC cell death in the early stage 
and proliferation in the late stage inversely, leading to less but slightly larger tumors after the 
AOM DSS treatment.  
 
Tumor incidence and progression in the AOM DSS model is not only driven by DSS induced 
colon inflammation [50], but also influenced by immune cell infiltration and activation in the 
developing tumors which can have pro- and anti-tumor activity [82]. Therefore, we analyzed 
the infiltrating immune cells in AOM DSS induced tumors at the end of the treatment.  
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The observation that effector T cell frequency was not altered in single housed CCL17-deficient 
mice indicated that the observed reduction in tumor number was not due to an increased T cell 
response against the tumors. The frequency of Tregs and Th17 cells which have been shown 
to migrate in response to CCL17 was not altered in the tumors of CCL17-deficient mice 
indicating that CCL17 is redundant for T cell migration to the tumors in this model. This is in 
contrast to findings in the syngeneic CT-26 tumor model, in which CCL17 and CCL22 have 
been shown to play a role for Treg migration [117, 118]. However, these studies focused on 
downregulation of CCL17 and CCL22 respectively in the CT-26 tumor cell line, while we did 
not observe CCL17 expression in CD45-negative cells in AOM DSS induced tumors. 
We did not find changes in the myeloid cell frequencies. As observed in DSS treated  APCMin/+ 
mice (but not in APC1638N/+ mice treated with AOM [34]) MHCIIlo cells were more abundant than 
MHCIIhi macrophages in AOM/DSS induced tumors [78]. Elevated levels of granulocytes or 
granulocytic MDSC are associated with increased tumorigenesis [119-122], whereas the role 
of TAMs appears to be more complex as both protective and protumorigenic effects have been 
observed [92, 113, 123, 124]. Therefore, we sought to not only determine the abundance but 
also the functional status of the non-granulocytic myeloid cell populations in the tumor by 
transcriptomic profiling. Interestingly, we found significantly enriched gene expression for 
lysosomal and proteasomal processes in monocytes and Ly6Clo MHCIIhi cells from tumors of 
CCL17-deficient single housed mice.  Lysosomal and proteasomal activity are crucial for 
antigen processing, therefore tumor antigen uptake and presentation might be enhanced in 
monocytes and Ly6Clo MHCIIhi cells from tumors of CCL17-deficient single housed mice [125]. 
Data showing downregulated antigen processing in Irf1-knockout mice, which develop 
increased numbers of AOM/DSS induced tumors indicate a functional relevance of this effect 
[121]. Additionally, proteasome inhibition was shown to dampen macrophage pro-inflammatory 
activity  [126]. Functional changes in the myeloid compartment might exert a protective effect 
in early stages of tumor development. Apart from lysosomal and proteasomal genes, we 
observed an enrichment in oxidative phosphorylation genes in monocytes and Ly6Clo MHCIIhi 
cells from tumors of CCL17-deficient single housed mice. Studies using in vitro differentiated 
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macrophages have shown a metabolic switch to glycolysis upon LPS/IFN-g stimulation (M1 
polarization) and to oxidative phosphorylation upon M2 polarization with IL-4/IL-13 [127]. 
Further, the immunosuppressive phenotype of TAMs coincided with increased oxidative 
phosphorylation (OXPHOS) in several tumor models  [128]. However, more recent studies 
report increased glycolysis instead of increased OXPHOS in suppressive TAMs [129, 130]. 
Similarly, Soncin et al. show higher glycolytic activity in the Arg1+ immunosuppressive 
macrophage population in colon tumors of DSS treated APCMin/+ mice [78]. Thus, transcriptome 
analysis indicates functional and metabolic alterations in monocytes and Ly6Clo MHCIIhi cells 
from CCL17-deficient single housed mice, which are potentially relevant for tumor incidence 
and growth. Additionally, functional alterations of the myeloid tumor infiltrating cells in CCL17-
deficient single housed mice are also indicated by reduced levels of secreted IL-1β. Elevated 
levels of IL1-β have been associated with increased AOM/DSS induced tumorigenesis  [131, 
132]. Further, NLRC4 mediated IL-1β production has been shown to be influenced by the 
microbiota [133]. Thus, reduced levels of secreted IL1β in the tumor microenvironment might 
play a protective role in the AOM/DSS induced tumorigenesis in single housed CCL17-
deficient mice by e.g. reducing angiogenesis in tumors of CCL17-deficient mice during the 
tumor initiation phase  [134, 135].  
 
Our results show increased CCL17 expression in AOM/DSS induced colonic tumors by 
myeloid cell populations with relevant functions for tumor induction and progression. Tumor 
initiation was reduced in single housed CCL17-deficient mice, which showed changes of the 
microbiota, possibly mediated by increased luminal IgA levels in these mice. Decreased tumor 
initiation might be caused by elevated apoptosis levels in the early phase of AOM/DSS 
treatment. Further, changes in myeloid cell functionality in tumors of single housed CCL17-
deficient mice coincide with the protective effect in this colon tumor model. Thus, CCL17 
influences AOM/DSS induced tumorigenesis on multiple levels, leading to reduced tumor 
multiplicity.  
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Supplementary Figure 1  
 
Supplementary Figure 1 (related to Figure 1): A Representative dot plots, showing GFP+ cell 
frequencies within CD45+ cells (left), CD45- cells (middle) and CD45+ non-DCs/macrophages in steady 
state (top), inflammatory (middle) colon tissue and AOM-DSS induced colon tumors (bottom). B Gating 
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Supplementary Figure 2  
 
Supplementary Figure 2 (related to Figure 2). A MFI of CD206, CD24 and CD209a on tumor 
infiltrating GFP+ cells, cDC2, total DCs and MHCIIhi macrophages. Mean ± SEM. Each data point 
represents pooled tumors (similar size) of one mouse (n ≥ 4). B Left. Gating strategy used for population 
sorting for subsequent gene expression analysis. Right: M1 (top) and M2 (bottom) marker gene 
expression in the sorted populations (from left to right: p1-p4). Mean ± SEM. Each data point represents 
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Supplementary Figure 3 
 
Supplementary Figure 3 (related to Figure 6): A Frequency of B220+ cells. Each data point 
represents one mouse (n ≥ 4). Mean ± SEM. B T cell frequencies in ctrl, ki SiHo and ki CoHo tumors 
(left). Representative contour plots (right). Each data point represents one mouse (n ≥ 4). Mean ± SEM. 
C Representative tumor cryosections from ctrl, ki SiHo and ki CoHo mice, stained for CD3 (red) and E-
Cadherin (grey). Dashed lines highlight tissue edges. Scale bar: 10 µm. D Percentages of CD4+, Treg 
and CD8+ T cell subsets (left) and NK and NKT cells (right)  in tumors of ctrl, ki SiHo and ki CoHo mice. 
Each data point represents one mouse (n ≥ 4). Mean ± SEM. E Percentages of IFN-ɣ-expressing cells 
(left) and IL-17-expressing cells (right) in tumors of ctrl, ki SiHo and ki CoHo mice. Each data point 
represents one mouse (n ≥ 4). Mean ± SEM. F Geometric mean of CD69 on CD4+, CD8+ T cells, NK 
cells and NKT cells in tumors of ctrl, ki SiHo and ki CoHo mice. Each data point represents one mouse 
(n ≥ 4). Mean ± SEM. G Relative gene expression of gzmb, il17 and ifng in tumors of ctrl, ki SiHo and ki 
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Supplementary table 1 antibodies used for flow cytometry 
Reagent/Resource Source Cat.no. Clone Dilution 
anti-mouse Ly6C-AF700 Biolegend 128024 HK1.4 1:200 
anti-mouse MHCII-BV421 Biolegend 107631 M5/114.15.2 1:300 
anti-mouse CD64-PE-Dazzle-594 Biolegend 139319 X54-5/7.1 1:150 
anti-mouse F4/80-PE-Dazzle-594 Biolegend 123145 BM8 1:200 
anti-mouse CD103-PE 
BD 
Bioscience 557495 2E7 1:150 
anti-mouse CD11b-APC-Cy7 Biolegend 101226 M1/70 1:300 
anti-mouse CD24 BV605 Biolegend 101827 M1/69 1:200 
anti-mouse CD209a APC Thermo 17-2092-80 LWC06 1:200 
anti-mouse CD13 BV421 
BD 
Bioscience 564354 R3-242 1:200 
anti-mouse CD206 AF647 Biolegend 141712 C068C2 1:150 
anti-mouse CD45 PerCP Biolegend 109828 104 1:300 
anti-mouse Ly6G BV650 Biolegend 109828 1A8 1:200 
anti-mouse CD11c PE-Cy7 Biolegend 117318 N418 1:400 
anti-mouse B220 BV605 Biolegend 103244 RA3-6B2 1:200 
anti-mouse CD3 APC-Cy7 Thermo 47-0031-82 145-2C11 1:200 
anti-mouse CD4 BV605 Biolegend 100548 RM4-5 1:200 
anti-mouse Foxp3 PE-Cy7 Thermo 25-5773-80 FJK-16a 1:200 
anti-mouse CD8 AF700 Biolegend 100729 53-6.7 1:200 
anti-mouse NK1.1 BV650 Biolegend 108735 PK136 1:200 
anti-mouse IL-17A APC Thermo 17-7177-81 eBio17B7 1:200 
anti-mouse IFNɣ PE 
BD 
Bioscience 108736 XMG1.2 1:200 
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anti-mouse CD69 V450 
BD 
Bioscience 560690 H1.2F3 1:200 
anti-mouse IgA PE Thermo 12-4204-81 mA-6E1 1:125 
Supplementary table 2 primer probe sets 
Target Source Identifier 
Bax Thermo Mm00432051_m1 
Bcl2 Thermo Mm00477631_m1 
Ccl17 Thermo Mm01244826_g1  
Ccl2 Thermo Mm00441242_m1 
Csf2 Thermo Mm01290062_m1  
Cxcl10 Thermo Mm00445235_m1 
Cxcl13 IDT Mm.PT.58.31389616 
Cxcl2 Thermo Mm00437121_m1  
Gzmb Thermo Mm00442837_m1 
Hprt IDT Mm.PT.39a.22214828 
Ifng Thermo Mm99999071_m1  
Il12a Thermo Mm00434169_m1  
Il17a Thermo Mm00439619_m1  
Il1b Thermo Mm00434228_m1 
Il22 Thermo Mm00444241_m1  
Il23a IDT Mm00518984_m1 
IL6  Thermo Mm00446190_m1  
Muc2 Thermo Mm01276696_m1 
Pcna IDT Mm.PT.58.3320736 
Reg3g Thermo Mm00441127_m1 
Tnf Thermo Mm00443258_m1 
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Colorectal cancer (CRC) is one of the most common cancers and a major cause of
mortality. Mice with truncating Apc germline mutations have been used as a standard
model of CRC, but most of the Apc-mutated lines develop multiple tumors in the
proximal small intestine and rarely in the colon precluding detailed analysis of colon tumor
microenvironment. Our aim was to develop a model with higher resemblance to human
CRC and to characterize tumor infiltrating immune cells in spontaneously developing
colon tumors compared to small intestinal tumors. Therefore, the Apc1638N/+ line was
treated repeatedly with azoxymethane (AOM) and 90% colon tumor incidence and 4 to 5
colon tumors per mouse were achieved. Of note, AOM treatment specifically increased
the tumor burden in the colon, but not in the small intestine. Histological grading and
WNT-signaling activity did not differ significantly between small intestinal and colon
tumors with some lesions progressing to invasive adenocarcinoma in both locations.
However, characterization of the intratumoral myeloid cell compartment revealed a
massive infiltration of colon tumors with neutrophils − 6-fold higher than in small intestinal
tumors. Moreover, CCL17-expressing macrophages and dendritic cells accumulated in
the tumors indicating the establishment of a tumor-promoting immunosuppressive
environment. Thus, Apc1638N/+ mice treated with AOM are a suitable and straightforward
model to study the influence of immune cells and chemokines on colon carcinogenesis.
Keywords: colorectal cancer, mouse model, adenomatous polyposis coli, azoxymethane, tumor immunology and  
microenvironment, tumor-associated neutrophils, tumor-associated macrophages, dendritic cells
INTRODUCTION
Colorectal cancer (CRC) is one of the most prevalent cancers worldwide, and one of the leading
causes of cancer-related morbidity and mortality, especially in countries with “Western” life style.
Aberrant WNT signaling plays an important role in initiation of human colorectal carcinogenesis.
Loss of the adenomatous polyposis coli (APC) tumor suppressor is not only the
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cause of familial adenomatous polyposis, but also 80–90% of
sporadic CRC harbor loss of function mutations—mostly
truncating nonsense mutations—in the APC gene (1). The
second APC allele is inactivated by promoter methylation,
chromosomal loss, or additional mutations leading to biallelic
loss (loss of heterozygosity, LOH) or inactivation of APC (2, 3).
As a result, β-catenin is not degraded, accumulates and
translocates to the nucleus where it acts as a transcriptional
coactivator inducing the expression of WNT target genes
including c-Myc, Cyclin D1, and osteopontin which promote
proliferation and ultimately tumor formation (2, 4). Additional
mutations, e.g., in KRAS, PTEN, PIK3CA, TGFBR1, TGFBR2,
SMAD2, SMAD4, and TP53 are found in APC-mutated sporadic
CRC, which promote tumor progression. In contrast, CRC
lacking APC mutations are frequently associated with mutations
in mismatch repair genes (2).
Mice heterozygous for truncating germline mutations of Apc,
such as the ApcMin/+ line on C57BL/6 background (5) have been
used for decades as a preclinical model. A major disadvantage of
the frequently used ApcMin/+ model is however that the mice
quickly develop multiple adenomas in the small intestine (SI),
and only few polyps in the colon, which leads to a life span of <6
months on the C57BL/6 background (2). Further, progression of
these lesions to invasive adenocarcinoma is very rare (2).
Apc1638N/+ mice were generated by inserting a neomycin
cassette in antisense orientation into exon 15, resulting in chain
termination at codon 1638 and production of an unstable protein.
These mice develop intestinal adenomas and adenocarcinomas,
which was attributed to somatic loss of the wildtype Apc allele (6)
or rather Apc mutations as described in a more recent publication
(7). In comparison to ApcMin/+ mice the Apc1638N/+ mice
develop less tumors with longer latency and show progression to
invasive adenocarcinomas, as well as splenomegaly and desmoid
formation, thus more closely resembling human CRC. Although
colon tumors develop in Apc1638N/+ mice, their incidence and
number is low and their formation takes 10–12 months (2, 6, 8).
Treating Apc1638N/+ mice with “Western style” diet (9) or
crossing them with other genetically engineered mutant or
knockout mice (6, 10–17) promotes multiplicity and sometimes
progression of tumors in SI and/or colon. Similarly, conditional
knockout of Apc in colonic epithelial cells leads to selective colon
tumor formation (18, 19).
However, mice carrying several mutant or transgenic alleles
are cumbersome to work with for mechanistic studies, which
require crossing these models with additional knockout or
transgenic mice. Moreover, when using a Cre-mediated knockout
of Apc in colonic epithelial cells for tumor formation, alternative
recombinase systems need to be used for conditional gene
knockouts in other cell types.
Induction of colitis by administration of dextran sodium
sulfate (DSS) greatly accelerates adenoma and adenocarcinoma
formation in the colon of ApcMin/+ mice (20, 21), but this model
is not suitable to study tumorigenesis in the absence of overt
inflammation, which would better mimick human CRC
pathogenesis. Administration of azoxymethan (AOM), an
alkylating agent that produces free radicals, to C57BL/6
mice leads to low incidence tumor formation in the colon by
causing mutations in β-catenin (22). AOM treatment increased
incidence and numbers of colon adenomas and adenocarcinomas
in adult ApcMin/+ mice (23) and in young or neonatal ApcMin/+
mice, but these mice still had a predominance of small intestinal
tumors and a short life span (24–26). The histological features
of tumors from these mice have been described but a detailed
characterization e.g., regarding immune cell infiltration is
lacking.
Studies performed in the ApcMin/+ model indicate that
tumors are controlled by the adaptive immune system (27, 28).
However, regulatory T cells and myeloid cells, such as tumor
associated neutrophilic granulocytes (TAN) and monocytic cells
(functionally described as myeloid derived suppressor cells,
MDSC) as well as tumor associated macrophages (TAM) together
shape the tumor microenvironment to promote tumor growth
and to limit the anti-tumor immune response (29–33). A
subpopulation of TAMs isolated from subcutaneous tumor
models was shown to secrete CCL17 as a hallmark of M2-like
macrophage polarization (34). Unfortunately, the low incidence
and number of spontaneous colon tumors in ApcMin/+ and
Apc1638N/+ mice precludes a detailed characterization of immune
cell infiltrates including TAMs and TANs in spontaneously
developing colon tumors. We therefore established an accelerated
Apc1638N/+ model which is suitable for further investigations of
the tumor microenvironment and anti-tumor immune responses
in spontaneously forming colon tumors. In this study we show
that repeated administration of AOM to Apc1638N/+ mice leads
to a higher incidence and an increased number of tumors in the
colon and shortens experimental time to 6–7 months.
RESULTS
Repeated Injection of AOM Leads to  
Higher Incidence and Multiplicity of Colon  
Tumors and Decreased Survival in
Apc1638N/+ Mice
To generate more colon tumors in a shorter experimental time,
adult C57BL/6 mice carrying one CCL17-eGFP knock- in allele
as a reporter for CCL17 expression received weekly AOM
injections for 6 weeks, and were followed by clinical assessment
until anemia was clinically apparent or other criteria for
euthanasia were reached (Figure 1A). While the number of
colon tumors per mouse (Figure 1B) was significantly higher in
AOM treated vs. untreated Apc1638N/+ mice (median 3 vs. 0;
mean ±SEM 4.3 ±0.8 vs. 0.3 ±0.2), the number of macroscopically
visible tumors in the SI was slightly reduced in AOM treated vs.
untreated Apc1638N/+ mice (median 3 vs. 5; mean ±SEM 4.0 ±0.6
vs. 5.8 ± 0.7). Survival time was significantly reduced in AOM
treated Apc1638N/+ mice with a median survival time of 193 days
compared to 312 days in untreated mice (Figure 1C). The
cumulative incidence of colon tumor development increased 6-
fold from 15 to 90% after the administration of AOM, with a
5.7-fold higher relative risk for colon tumor development with
AOM treatment (p < 0.0001,
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FIGURE 1 | Increased incidence and number of colon tumors in AOM-treated APC1638N/+ mice. (A) Experimental scheme. Apc1638N/+ mice received weekly i.p. 
injections of AOM from age 8 to 14 weeks and were sacrificed when reaching criteria for euthanasia. (B) Number of tumors in small intestine (Si) and colon (Co) in  
untreated (n = 19) and AOM-treated (n = 31) mice (Mann–Whitney test). (C) Kaplan-Meier survival analysis (log-rank test). (D) Tumor incidence in Si and Co
(Chi-square analysis). (E) Representative macroscopic image of colon tumors in untreated and AOM-treated Apc1638N/+ mice. Scale bar: 1 cm. (F) Tumor sizes of Si  
and Co tumors (Si untreated: n =  103, Si AOM: n =  150, Co untreated: n =  5, Co AOM: n =  189, *p < 0.0001, Mann–Whitney test). *p <0.05.
Chi-square test, Figure 1D). Colon tumors were macroscopically
similar and were localized in the distal half of the colon in
AOM treated and untreated Apc1638N/+ mice (Figure 1E).
Interestingly, tumors in the SI were found to be significantly
smaller in the AOM-treated mice (median 1.3 vs. 5.3 mm2;
Figure 1F).
Thus, administration of AOM to adult C57BL/6 Apc1638N/+
mice specifically accelerates tumor development in the colon,
but not in the small intestine leading to a higher incidence and
multiplicity of colon tumors.
AOM-Treated Apc1638N/+ Mice Develop  
Highly Proliferative Colon Tumors With  
Active Wnt Signaling and Aberrant  
Accumulation of β-Catenin
Histopathological examination of tissue sections from colon
and SI tumors at the time points of sacrifice revealed low grade
and high grade intraepithelial neoplasia (IEN) with distorted
crypt architecture, high nuclear to cytoplasmic ratio, and
elongated stratified hyperchromatic nuclei, which
Frontiers in Oncology | www.frontiersin.org 3 October 2019 | Volume 9 | Article 1001
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in high grade IEN reached the luminal side. In some tumors
invasion of the muscularis mucosae with stromal and
inflammatory reactions was observed indicating progression to
adenocarcinoma (Figure 2A). Low grade IEN, high grade IEN
and occasionally adenocarcinomas were detected in intestinal
tumors of both AOM-treated and untreated mice. High grade
IEN was observed in colon tumors from AOM treated mice (6/9),
but not in SI tumors of AOM treated mice (0/4) (Figure 2A).
Expression of canonical Wnt target genes, such as the
stemness marker Leucine-rich repeat-containing G-protein
coupled receptor 5 (Lgr5) (35) and osteopontin (Opn, Spp1) (4) on
mRNA level was significantly higher in SI and colon tumors in
comparison to normal intestinal tissue. A trend towards higher
expression of Lgr5 and Opn in colon tumors of AOM treated
Apc1638N/+ mice was observed (Figure 2B, upper panels). Strong
β-catenin staining with cytoplasmic and nuclear localization [in
contrast to membranous staining found in normal epithelium
(4, 36)] was detected in all tumors with a trend toward a higher
proportion of nuclear β-catenin staining in AOM-treated mice
(Figure 2B, lower panels). Ki67 staining in tumor tissue sections
confirmed the high percentage of proliferating cells in the
tumors (representative result shown in Figure 2C, lower panel).
Accordingly, expression of Proliferating cell nuclear antigen
(Pcna) mRNA was significantly higher in colon tumors
compared to normal colon tissue and slightly higher in colon
tumors of AOM treated than untreated mice (Figure 2B). Thus,
tumors developing in AOM-treated Apc1638N/+ mice are highly
proliferative and show aberrant distribution of β-catenin and
active WNT signaling.
Comparison of Immune Cell Infiltrates in  
Small Intestinal and Colon Tumors Reveals  
Preferential Accumulation of Neutrophilic  
Granulocytes in Colon Tumors
Immune cell infiltrates in human colorectal cancer are an
important prognostic factor. Tumors in SI and colon of both
AOM treated and untreated mice were strongly infiltrated with
CD45+ cells (Supplementary Figures 1, 2). These were localized
below the neoplastic epithelium either distributed throughout
the tumor or forming clusters (Supplementary Figure 2). In all
tumors CD45+ cells contained a substantial proportion of T
lymphocytes, including CD4+ and CD8+ T cells as well as CD4+
Foxp3+ regulatory T cells and a smaller more variable
proportion of CD19+ B lymphocytes (Supplementary Figure 1).
CD11b+ myeloid cells — encompassing granulocytic and
monocytic cells as well as TAM and CD11b+ DCs — were less
frequent in SI tumors from AOM-treated than untreated mice
(24.1 ±6.1 vs. 53.2 ±7.0, mean ±SEM, p = 0.024;
Figure 3A). In contrast, AOM treatment did not seem to alter
the frequency of CD11b+ cells in colon tumors (Figure 3A).
Ly6Ghi CD11b+ neutrophilic granulocytes were 6-fold more
abundant in colon tumors than in SI tumors (AOM treated
mice: 59.4 ±23.2% vs. 19.5 ±13.9% of CD11b+ cells, p < 0.005)
(Figure 3B). The percentage of Ly6Ghi CD11b+ cells was greatly
increased in tumors compared to lamina propria of the same
AOM-treated Apc1638N/+ mice in both SI and colon
indicating active recruitment of neutrophilic granulocytes to
tumors in both locations, but preferential accumulation in colon
tumors (Supplementary Figure 2B). Within the CD11b+ Ly6G−
compartment the proportions of Ly6Chi MHCII− monocytic
cells, Ly6Chi MHCII+ intermediate cells, Ly6C− MHCIIhi CD64+
macrophages and Ly6C− MHCIIlo CD64+ macrophages were
similar in colon and SI tumors and not altered by AOM
treatment (Figure 3C). The frequency of DCs within CD45+
tumor infiltrating cells was not significantly different between
the experimental groups and the tumor locations (Figure 3D).
CCL2 and CXCL10, showed higher relative mRNA expression
levels in tumors than in normal lamina propria of tumor bearing
Apc1638N/+ mice (Figure 3E) correlating with the recruitment of
myeloid cells and T lymphocytes into the tumors.
Distinct Subpopulations of Tumor  
Infiltrating Myeloid Cells Shape the  
Intestinal Tumor Microenvironment
Programmed cell death ligand 1 (PD-L1) interacts with
Programmed cell death 1 (PD1) on effector T cells, NK cells and
TAMs inhibiting their anti-tumor activity. PD-L1 staining was
not detectable on CD45- tumor cells by flow cytometry (Figure
4B) but was found to be expressed on the surface of all myeloid
cell subsets within colon and SI tumors irrespective of AOM
treatment. Expression levels were highest in Ly6Chi MHCII−
followed by Ly6Chi MHCII+ monocytic cells and then MHCIIhi
and MHCIIlo TAM subsets (Figure 4A) We detected lower PD-
L1 expression on monocytes from the tumors than from lamina
propria (Figure 4B) indicating that the tumor
microenvironment is less inductive for PD-L1 expression than
the lamina propria.
CCL17 expression in the intestine is restricted to DCs in the
steady state (37, 38), but is also expressed by immunosuppressive
M2 polarized macrophages within tumors (34). Using Apc1638N/+
CCL17eGFP/+ reporter knockin mice (37) CCL17 expression
could be detected in TAMs and DCs in tumors of AOM (Figure
4C) at significantly higher levels than in normal lamina propria
of tumor bearing mice. Immunofluorescence staining of tumor
tissue sections showed infiltrates of CCL17eGFP expressing cells,
part of which stained positively for the DC marker CD11c
confirming our results from flow cytometric analysis (Figure
4D). Thus, the tumor microenvironment which is established in
colon and SI tumors of Apc1638N/+ mice favors CCL17
expression in TAMs and DCs.
DISCUSSION
In this study we show that repeated AOM injections increase
the incidence and multiplicity of colon tumors in mice with the
Apc1638N/+ germline mutation and shorten experiment time
while reducing the small intestinal tumor burden. Tumors
developing in AOM treated Apc1638N/+ mice express WNT
target genes and show aberrant accumulation of β- catenin, as
expected for WNT driven carcinogenesis. Strikingly,
comparison of immune cell infiltrates between colonic and SI
tumors revealed a significantly higher frequency of neutrophilic
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FIGURE 2 | AOM-treatment leads to the development of high-grade colonic lesions with active Wnt-signaling and proliferation. (A) Exemplary images of H&E stained  
cryosections of tumors isolated from AOM-treated and non-treated Apc1638N/+ mice (taken with 5×, 20×, and 63×objectives). Scale bars: 100 µm (5×), 25 µm
(Continued)
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FIGURE 2 | (20×), 10 µm (63×). Arrows indicate features of cell dedifferentiation and dysplasia such as pseudo-stratification, increased nucleus/cytoplasm ratios and  
abnormal nuclei positioning as well as invasion of the muscularis mucosae in adenocarcinomas. Proportions of low grade IEN, high grade IEN and adenocarcinoma  are 
shown in the graph (Si untreated, n =  5; Si AOM n =  4; Co untreated, n =  1; Co AOM, n =  9). (B) Upper panel: relative mRNA expression of WNT target genes  Lgr5 
and Opn in tumors and normal intestinal tissue from tumor-bearing mice was measured by qRT-PCR (fold-change compared to normal tissue average, log(10)  scale,
mean + SEM, n = 3–6). Lower panel, left: representative image of immuno-fluorescence staining for β-Catenin in cryosections of a colon tumor. Scale bar:
50µm. Zoomed images show nuclear and extranuclear localization of β-Catenin. Green: β-Catenin, blue: DAPI, 63× magnification. Right: quantification of nuclear
β-Catenin staining of total β-Catenin staining in one field of view per mouse. Symbols indicate tumors from individual mice; mean +  SEM (n =  2–3). (C) Upper panel:  
relative mRNA expression of Pcna in tumors and normal intestinal tissue from tumor-bearing mice was measured by qRT-PCR (fold-change compared to normal  tissue 
average, log(10) scale, mean +  SEM, n =  3–6, unpaired, two-tailed t-test). Lower panel: representative Ki67 staining of intestinal tumor tissue of an  Apc1638N/+ mouse 
(20×, red: Ki67, blue: DAPI, Scale bar: 50 µm). *p < 0.05.
granulocytes in colon tumors. Further, increased expression of
CCL17 in DCs and M2-like TAMs within tumors compared to
intestinal lamina propria indicates the establishment of a tumor-
promoting immunosuppressive environment. Thus, AOM
treated Apc1638N/+ mice can be used as a model of early colon
carcinogenesis to further investigate the interplay of immune
cells, stromal cells, and cancer cells in the tumor
microenvironment.
Repeated AOM administration has been used previously as a
model for sporadic CRC. A sufficient incidence of colon tumors
can be achieved by AOM administration in the susceptible A/J
strain but not in the C57BL/6 strain (39), which is the background
of the majority of genetically engineered mouse lines, e.g., for
functional studies of relevant immune cell types. Therefore, we
sought to combine Apc1638N/+ mutant mice with AOM treatment
and observed greatly increased incidence and multiplicity of
colon tumors, demonstrating a synergistic effect of the truncating
Apc1638N/+ mutation and AOM-induced mutations, which led
to increased cytoplasmic and nuclear accumulation of β-catenin
and upregulation of canonical WNT targetgenes.
Besides the slightly reduced number of small intestinal
tumors, their size was reduced and the majority showed low
grade IEN in AOM treated Apc1638N/+ mice. This is probably due
to the earlier termination of the experiment and demonstrates
that AOM is specifically affecting the colon. Histologically, high
grade IENs and invasive adenocarcinomas were found with
comparable frequency in 5–7 months old AOM treated
Apc1638N/+ mice as in 10–12 months old untreated Apc1638N/+
mice. Thus, AOM treatment accelerated tumor progression, but
did not lead to deeper tissue invasion beyond the bowel wall or
to metastasis. An increased incidence and number of colon
tumors was also reported in Apcmin/+ mice after repeated AOM
treatment (23, 24, 26, 40). However, Apcmin/+ mice have a much
higher spontaneous tumor burden in the small intestine, and
therefore a shorter life time that precludes further progression
of lesions along the adenoma-carcinoma sequence. The AOM
treated Apc1638N/+ mice in the present study provide the
opportunity to assess the influence of additional risk factors and
immune responses on both, lesion incidence and progression to
invasive carcinoma. It was shown in a recent study that
administration of AOM alone or combined with Citrobacter
rodentium infection increased proliferation and Dclk1-positive
cancer stem cell frequency in intestinal tumors of Apc1638N/+
mice indicating enhanced tumorigenesis in line with our results
(41). However, the impact of AOM administration on tumor 
multiplicity and progression was not reported in this publication. 
Comparison of small intestinal and colon tumors revealed that 
neutrophilic granulocytes marked by CD11b and Ly6G 
expression are massively recruited and dominate the myeloid cell  
infiltrate in colon tumors but not small intestinal tumors. This 
shows that location has a great impact on the composition of 
immune cell infiltrates in intestinal tumors, but the regulation 
of this preferential accumulation of neutrophilic cells in colon 
tumors is not known. Intratumoral CD11b+ Ly6-Ghigh cells 
consist of classical neutrophils (TANs) and/or pathologically 
activated immunosuppressive PMN-MDSC, which accumulate 
in the tumors, but are also found in blood, spleen and bone 
marrow of tumor bearing mice. TANs are heterogeneous and can 
have anti-tumor or protumor activity. Their prognostic role in 
CRC is controversial (42, 43). Although it was shown recently 
that neutrophils can limit tumor progression in the very early 
phase of murine CRC models by restricting tumor-associated 
bacteria and inflammatory responses (44), the majority of 
reports provide evidence for a tumor supporting role of TANs. 
PMN-MDSC, which develop at later stages, are by definition 
immunosuppressive and promote tumor initiation, progression
and dissemination (43).
Accumulation of neutrophils/PMN-MDSCs in small intestinal
and colon tumors of Apc1638N/+ mice correlated with increased
expression of CCL2 compared to normal intestinal tissue with
slightly higher expression in colon tumors. Chun et al. also
reported increased CCL2 expression in colitis associated colon
cancer, sporadic CRC as well as precancerous colorectal lesions
in humans and in mouse models (45). In these models CCL2
was shown to be required for PMN-MDSC and M- MDSC
accumulation in the tumors and enhanced the T cell
suppressive function of PMN-MDSC (45). In addition to CCL2,
CXCR2 ligands including CXCL1, CXCL2, CXCL3, and CXCL8
produced by CRC cells and neutrophils themselves were found
to be responsible for recruitment of CXCR2+ neutrophils/PMN-
MDSCs to colon tumors (46–48). We have shown earlier that
specific colon microbiota in human patients are correlated with
chemokine production and infiltration of immune cell subsets
(49). Preferential recruitment of neutrophilic cells to colon
tumors vs. small intestinal tumors could therefore involve site-
specific microbiota signals and inflammatory responses (50), but
also genetic mechanisms of tumor initiation, which differ
between tumor locations in the intestine (7).
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FIGURE 3 | Accumulation of granulocytes in intestinal tumors correlates with chemokine expression and is enhanced in colon tumors. (A) Representative contour plot  of
intratumoral (AOM treated colon tumor) immune cells stained for MHCII and CD11b, showing the gating for CD11b+ cells. The percentages of CD11b+ cells of all
(Continued)
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FIGURE 3 | CD45+ cells in Si and Co tumors of untreated and AOM treated Apc1638N/+ mice are shown in the graph. (B) Representative dot plot of intratumoral  
CD45+ immune cells stained for Ly6G and CD11b, showing the gating for CD11b+ Ly6G+ granulocytic cells. The percentages of CD11b+ Ly6G+ cells of all  CD11b+ 
cells are shown in the graph. (C) Gating strategy for monocytes (Mono), intermediate monocytes (int. Mono), and MHCIIlo/hi macrophages within the  intratumoral 
CD11b+ Ly6G− population. The percentages of the indicated populations within the CD11b+ Ly6G− cells are shown in the graph. (D) Gating strategy  for intratumoral DCs 
and frequency of DCs within CD45+ cells. (A–D) Each symbol represents an individual mouse. Horizontal bars indicate mean, error bars indicate  SEM, n =  2–9. (E) 
Relative mRNA expression of the chemokines CCL2 and CXCL10 in tumors and normal intestinal tissue from AOM-treated and untreated  Apc1638N/+ mice measured 
by qRT-PCR [fold-change compared to normal tissue, log(10) scale]. Symbols indicate individual mice, horizontal bars: mean, error bars:  SEM, n =  3–6, unpaired, two-
tailed t-test. *p <0.05.
FIGURE 4 | PD-L1 and CCL17 (eGFP) expression in intestinal tumors indicates establishment of a tumor promoting microenvironment. (A) PD-L1 mean fluorescence  
intensity (MFI) of the indicated myeloid cell populations in Si and Co tumors of untreated and AOM treated Apc1638N/+ mice. Representative histogram overlay of the  
PD-L1 fluorescence signal in the indicated myeloid cell populations (colored histograms) and CD45-negative tumor cells (gray histogram) from colonic intratumoral  cells 
of an AOM-treated mouse. (B) Representative histogram overlay of the PD-L1 fluorescence signal in monocytes from tumor (light gray, open histogram) and  normal 
(dark gray, open histogram) tissue, compared to CD45-negative cells (gray, filled histogram) from colonic intratumoral cells of an AOM-treated mouse. (C)  CCL17-eGFP 
expression was detected by flow cytometry in macrophages and DCs in tumors and normal lamina propria of Apc1638N/+;CCL17-eGFP-reporter mice.  The 
percentages of GFP+ cells within the indicated populations are shown. (A,C) Each symbol represents an individual mouse. Horizontal bars: mean, error bars:  SEM, n =
2–9, unpaired two-tailed t-test. (D) Immunofluorescence staining (left: 20×magnification, scale bar 50 µm) of Si tumor tissue of an AOM-treated mouse.
Blue: nuclear staining (DAPI), red: CD11c, green: CCL17-reporter (eGFP). *p < 0.05.
Further investigation of tumor infiltrating myeloid cells in
intestinal tumors of AOM-treated and untreated Apc1638N/+
mice confirmed the presence of all subpopulations of monocytes,
macrophages and DCs with comparable frequencies in small
intestinal and colon tumors. PD-L1 was expressed on tumor-
infiltrating monocytic cells, albeit at lower levels than in colon
lamina propria. But macrophages, granulocytes and DCs showed
only low level expression mimicking the situation in human
CRC, where low PD-L1 expression correlates with poor response
to PD-1 blockade (51). Successful therapy with pembrolizumab
(anti-PD-1) is restricted to the subgroup of mismatch repair
deficient CRC which show higher PD-L1 expression (mainly in
tumor-associated immune cells) (52). Thus, our model is
suitable for investigating regulation of PD-L1 expression in colon
tumors and testing therapeutic approaches, which aim to increase
responsiveness to checkpoint inhibition.
Using Apc1638N/+ CCL17-eGFP reporter mice, we found that
TAMs and DCs upregulate expression of CCL17 in the
microenvironment of small intestinal and colon tumors
developing in Apc1638N/+ mice. CCL17 expression has been used
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as a marker for M2-like immunosuppressive TAMs and was
shown to correlate with Treg frequencies in tumors in line with
its ability to attract Tregs expressing CCR4 (34, 53). Therapeutic
strategies targeting TAMs (such as CSF-1R inhibitors) were
shown to be effective in syngeneic subcutaneous tumor models,
but only in combination with immune stimulation or
checkpoint blockade (34, 54). Further studies are required to
identify novel target molecules, which prevent or revert the
immunosuppressive and tumor promoting functions of TAMs
and other tumor-infiltrating myeloid cell subpopulations in
spontaneously developing cancers, such as the CRC model
described here.
The model described here also allows assessing the phenotype
of diverse complete and conditional knockout mouse strains with
a simple breeding strategy since only one mutated Apc allele is
necessary, whereas Cre recombinase or complex husbandry
regimes are not required for colon tumor formation. This is
advantageous compared to models of conditional Apc deletion,
such as in Cdx2p-Cre; Apc+/Loxp mice (18, 19) or Fabpl- Cre;
Apc15lox/+ mice (55) or Villin-Cre; Tp53 Loxp/Loxp mice treated
with AOM which require backcrossing to the FVB background
(56).
We conclude that Apc1638N/+ mice treated with AOM are a
suitable and robust model of colon carcinogenesis and will be




Mice were bred and held in the animal facility of the Institute
for Immunology, LMU Munich, Germany under SPF
conditions. Health monitoring was performed according to the
recommendations of the Federation of European Laboratory
Animal Science Association (FELASA). Sentinels occasionally
tested positive for Helicobacter spp. All experimental procedures
involving mice were performed in accordance with the
regulations of and were approved by the local government
(Regierung von Oberbayern, license no: 55.2-1-54-2532-36-
2013). Apc1638N/+ mice (8) were crossed with CCL17-eGFP
reporter mice (37) (all kept on C57BL6/N-background for >10
generations). Starting at the age of 8 weeks mice were injected
with 10 mg/kg Azoxymethane (AOM) i.p. weekly for 6 weeks [as
described (56)] or were left untreated. Mice were sacrificed by
cervical dislocation when reaching criteria for euthanasia, which
included clinical signs of anemia.
Tissue Processing and Single Cell  
Preparation
The intestines were cut longitudinally, washed with ice-cold PBS
and the number, location and size of tumors was recorded. Visible
tumors were excised and randomly selected tumors were fixed in
4% PFA for 1 h at 4◦C and subsequently incubated in 20% sucrose
o/n at 4◦C. Tumors were then embedded in OCT (Leica, Wetzlar,
Germany) and stored in −80◦C. For the generation of single cell
suspensions remaining tumor and normal intestinal tissue was
cut into 5 mm long pieces and incubated with 2 mM DTT,
10 mM HEPES, 10 mM EDTA for 10 min in a shaking incubator
(125 rpm) to dissociate the epithelial layer and then digested
with DNAse (0.5 µg/ml), Collagenase D (2.5 µg/ml), Collagenase
V (5 µg/ml), and Collagenase IV (157 Wuensch Units/ml) in
RPMI-1640 for 30 min at 37◦C with gentle shaking before passing
through 100 and 70 µm cell strainers.
Histology
Cryosections (5–8 µm) were incubated in Hematoxylin solution
(Merck, Darmstadt, Germany), washed in H2O and subsequently
stained in Eosin solution (J.T. Baker, Philipsburg, USA), washed
in H2O, dehydrated and mounted with RotiⓍR -Histokitt (Carl
Roth, Karlsruhe, Germany). Histological assessment and grading
was performed using a Leica DM2500 after consultation with a
pathologist.
Immunofluorescence Staining
Cyrosections (5–8 µm) were incubated with phosphate buffered
saline (PBS) containing 5% goat serum (Vector Labs, Burlingame,
USA) and 0.5% Triton-X-100 and then stained with primary
antibodies: anti-Ki67 (cat. #12202, Cell signaling technology,
Danvers, USA), anti-CD45-FITC (#11-0454-82, Thermo Fisher,
Waltham, USA), anti-GFP (#ab6556, Abcam, Cambridge, UK),
anti-CD11c (#550283, BD-Bioscience, Franklin Lakes, USA),
anti-β-Catenin (#ab22656, Abcam). In case of unlabeled primary
antibodies fluorochrome-labeled secondary antibodies were used
(#A11008, #A11001, #A21236 Molecular Probes, Eugene, USA).
For staining nuclei DAPI (Sigma-Aldrich, St. Louis, USA) was
used. Imaging was conducted with a Leica SP8X WLL upright
confocal microscope (Leica, Germany).
Flow Cytometry
Single cell suspensions from normal or tumor tissues, processed
as described above, were incubated for 10 min with Fc-blocking
reagent (anti-CD16/32 producing hybridoma supernatant)
before staining with fluorescently labeled surface antibodies,
purchased from Biolegend (CD4, #100547, CD8, #100730, CD19,
#115522, MHCII, #107632, CD11b, #101226, Ly6G, #127641,
CD64, #139305, CD11c, #117318) and Thermo Fisher (CD3, #47-
0031-82, Foxp3, #25-5773-80). For Foxp3-staining the Foxp3-
Fix/Perm buffer kit was used according to the manufacturers
protocol. The Cytoflex S flow cytometer (Beckman Coulter, Brea,
USA) was used and the data were analyzed using FlowJo v. 10
(Tree Star Inc., Ashland, USA).
RNA Isolation and qRT-PCR
RNA was isolated from OCT-embedded tissue sections using
the RNeasy-FFPE Kit (Qiagen, Hilden, Germany) according to
the manufacturers protocol. RNA was reverse-transcribed using
SuperScript III (Thermo Fisher). For qRT-PCR UPL
primer/probe sets for Lgr5, Opn, Ccl2, Cxcl10 (probes: Roche
Diagnostics, Rotkreuz, Switzerland; primers: Metabion, Planegg,
Germany) or Taqman assays for Hprt1 (Thermo Fisher) were
used and qPCR was performed on a LightCycler 480 Real-Time
PCR system (Roche). The 2∧-ddCT method was used to quantify
relative mRNA expression.
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Statistical Analysis
Statistical analysis was performed with GraphPad Prism version
6.0 (GraphPad Software Inc., La Jolla, CA, USA). Normally
distributed data was analyzed by unpaired or paired two-tailed
t-test. Not normally distributed data was analyzed using the
Mann-Whitney test. For multiple testing the Holm-Sidak
correction method (alpha = 0.05) was used. Survival was
analyzed by Kaplan-Meier analysis and log-rank test. The Chi-
square test was used to assess relative risk.
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(A) Percentages of CD45+ immune cells in tumors of untreated and AOM-treated
Apc1638N/+ mice. (B) Percentages of CD3+ T cells, CD4+ T-helper cells, CD4+ Foxp3+
Treg cells and CD19+ B cells of all CD45+ cells in tumors of untreated and AOM-treated
Apc1638N/+ mice. Each symbol represents an individual mouse. Horizontal bars: mean,
error bars: SEM, n=2-9, unpaired two-tailed t-test (not significant).
Supplementary figure 2:
(A) Representative images of CD45 (red) immunofluorescence staining (20x
magnification) of small intestinal tumor tissue from untreated (left) and AOM-treated
(right) Apc1638N/+ mice. (B) Percentages of indicated immune cell populations of all
CD45+ cells in Si and Co tumor lesions (grey, filled bars) and normal intestinal tissue
(open bars) of the same individual AOM-treated Apc1638N/+ mice. Each symbol
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